GalNAc compounds, conjugates, compositions and uses thereof

By designing high-affinity GalNAc compounds and conjugating them with oligonucleotides, the problem of insufficient affinity of ASGPR ligands was solved, achieving liver-targeted delivery and target gene inhibition, with efficient and safe drug delivery.

CN119019475AActive Publication Date: 2024-11-26RIGERNA THERAPEUTICS (BEIJING) CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310596547.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-26
Estimated Expiration
2043-05-24

AI Technical Summary

Technical Problem

In the existing technology, the ligand affinity of the desialyl glycoprotein receptor (ASGPR) is not high, resulting in poor liver-targeted delivery of drugs or genes and difficulty in effectively regulating the expression of target genes.

Method used

The GalNAc compound was designed and synthesized to achieve liver-targeted delivery of oligonucleotides through high affinity binding with ASGPR. Specifically, GalNAc compounds were conjugated with oligonucleotides to form highly efficient conjugates for the treatment and/or prevention of liver-related diseases.

Benefits of technology

It achieves highly effective targeting of oligonucleotides to the liver, significantly inhibits the expression of liver target genes, and has higher in vivo activity, more stable and long-lasting efficacy, and excellent safety with low animal-level toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_9
    Figure SMS_9
  • Figure SMS_16
    Figure SMS_16
Patent Text Reader

Abstract

The present disclosure relates to the field of drugs, in particular to GalNAc compounds, conjugates, compositions and uses thereof. The oligonucleotide conjugate provided by the disclosure is synthesized through the GalNAc compound provided by the disclosure, and the oligonucleotide conjugate can highly and effectively target to parenchymal hepatic cells, can effectively inhibit target gene expression in the parenchymal hepatic cells, and can be used for treating and / or preventing liver-derived diseases, particularly liver-derived diseases. The compound has the advantages of high in-vivo activity, stable and lasting drug effect, excellent safety and low toxicity at an animal level.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of medicine, and in particular to GalNAc compounds, conjugates, compositions and uses thereof. Background Art

[0002] The asialoglycoprotein receptor (ASGPR), also known as liver lectin, is a transmembrane protein that is prominently and specifically expressed on the cell surface of the liver sinusoids and basolateral side. ASGPR is mainly composed of two subunits, H1 and H2, which together have an endocytic effect. A normal mature hepatocyte has about 500,000 receptor molecules, and about 10% of ASGPR are expressed on the cell membrane. They have the specificity to recognize, bind to, and internalize some glycoproteins with galactosyl and N-acetylgalactosyl at the ends of the blood circulation, allowing them to be metabolized in hepatocytes. Oligonucleotides are conjugated with targeting ligands, and the targeting ligands are used to bind to ASGPR to achieve liver-targeted delivery of oligonucleotides.

[0003] However, the affinity of ASGPR ligands is currently low, which cannot effectively achieve liver-targeted delivery of drugs or genes to achieve the purpose of regulating target gene expression. Summary of the invention

[0004] In view of this, the present disclosure provides GalNAc compounds, conjugates, compositions and uses thereof.

[0005] The oligonucleotide conjugates provided by the present disclosure can be highly effectively targeted to the liver and effectively inhibit the expression of liver target genes, can be used to treat and / or prevent hepatic diseases, have higher in vivo activity than control vectors, more stable and lasting pharmacodynamic effects, and are expected to have excellent safety and low animal-level toxicity.

[0006] In order to achieve the above-mentioned invention object, the present disclosure provides the following technical solutions:

[0007] In the first aspect of the present disclosure, the present disclosure provides a compound having a structure represented by formula (Ia) or a stereoisomer thereof, a pharmaceutically acceptable salt or a prodrug thereof:

[0008]

[0009] In formula (Ia), R1 is selected from H, a hydroxyl protecting group or The * represents a connection site for connecting a drug active molecule;

[0010] The R2 is selected from H, a reactive phosphorus group or Among them, R 2bSelected from a solid phase carrier containing an amino functional group, R 2a A covalent linking group selected from the group consisting of a covalent linking group connected to the amino functional group;

[0011] The j is selected from 0, 1, 2 or 3;

[0012] Each M is independently selected from hydroxyl or thiol;

[0013] Each p is independently selected from 0, 1, 2, 3 or 4;

[0014] Each q is independently selected from 0, 1, 2, 3 or 4;

[0015] Each Cy is independently selected from wherein A is selected from a 5-6 membered oxygen-containing heterocyclic ring; R3 is selected from H or C1-C6 alkoxy; n is selected from 1 or 2; each X is independently selected from O, S, or NH; each R4 is independently selected from H, C1-C6 alkyl or C1-C6 alkoxy; each L1 is independently selected from a substituted or unsubstituted triazole group, or an amide group; m is selected from 1 or 2; each L2 is independently selected from a substituted or unsubstituted C1-C30 alkylene group or Each r is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, each Z is independently selected from O, S or NH, each R L2 Each is independently selected from substituted or unsubstituted C1-C10 alkylene; each Y is independently selected from O, S or NH; each R5 is independently selected from H, substituted or unsubstituted C1-C4 alkyl acyl or substituted or unsubstituted C6-C12 aryl acyl.

[0016] In some optional embodiments of the present disclosure, A is selected from a 5- to 6-membered saturated oxygen-containing heterocycle.

[0017] In some optional embodiments of the present disclosure, A is selected from a 5-6 membered saturated heterocyclic ring containing one oxygen atom.

[0018] In some optional embodiments of the present disclosure, the A is selected from

[0019] In some specific embodiments of the present disclosure, the A is selected from

[0020] In some specific embodiments of the present disclosure, the A is selected from

[0021] In some specific embodiments of the present disclosure, said m is selected from 1.

[0022] In some specific embodiments of the present disclosure, X is selected from O.

[0023] In some specific embodiments of the present disclosure, each R4 is selected from H.

[0024] In some optional embodiments of the present disclosure, each L1 is independently selected from

[0025] In some specific embodiments of the present disclosure, each L1 is selected from

[0026] In some specific embodiments of the present disclosure, each L1 is selected from

[0027] In some optional embodiments of the present disclosure, the R3 is selected from H or C1-C3 alkoxy.

[0028] In some specific embodiments of the present disclosure, the R3 is selected from H or methoxy.

[0029] In some specific embodiments of the present disclosure, R3 is selected from H.

[0030] In some specific embodiments of the present disclosure, the R3 is selected from methoxy.

[0031] In some optional embodiments of the present disclosure, each L2 is independently selected from Each r is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, each Z is independently selected from O, S or NH, each R L2 Each is independently selected from substituted or unsubstituted C1-C10 alkylene groups.

[0032] In some optional embodiments of the present disclosure, each L L2 Each is independently selected from substituted or unsubstituted C1-C5 alkylene.

[0033] In some optional embodiments of the present disclosure, each L L2 Each is independently selected from substituted or unsubstituted C1-C3 alkylene.

[0034] In some optional embodiments of the present disclosure, each L L2 Each is independently selected from substituted or unsubstituted C2 alkylene.

[0035] In some optional embodiments of the present disclosure, each r is independently selected from 2 or 3.

[0036] In some optional embodiments of the present disclosure, each L2 is independently selected from The r is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0037] In some specific embodiments of the present disclosure, each L2 is independently selected from The r is selected from 2 or 3.

[0038] In some specific embodiments of the present disclosure, each L2 is selected from

[0039] In some specific embodiments of the present disclosure, each L2 is selected from

[0040]

[0041] In some specific embodiments of the present disclosure, each Y is selected from O.

[0042] In some embodiments of the present disclosure, each R5 is independently selected from H,

[0043] In some specific embodiments of the present disclosure, each R5 is selected from

[0044] In some specific embodiments of the present disclosure, each R5 is selected from H.

[0045] In some embodiments of the present disclosure, said p and q are each independently selected from 0 or 1.

[0046] In some specific embodiments of the present disclosure, p=1 and q=1.

[0047] In some specific embodiments of the present disclosure, p=1 and q=0.

[0048] In some specific embodiments of the present disclosure, p=0 and q=1.

[0049] In some specific embodiments of the present disclosure, p=0 and q=0.

[0050] In the disclosure, the hydroxyl protecting group can be various hydroxyl protecting groups, and the specific type is not limited as long as it can protect the hydroxyl group. In some embodiments, the hydroxyl protecting group is stable under alkaline conditions, but can be removed under acidic conditions.

[0051] In some optional embodiments of the present disclosure, the hydroxyl protecting groups that can be used in the present disclosure include, but are not limited to, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, 9-phenylxanthine-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthine-9-yl (Mox), trityl (Tr group), 4-methoxytrityl (MMTr group), 4,4'-dimethoxytrityl (DMTr group) and 4,4',4"-trimethoxytriphenyl (TMTr group).

[0052] In some optional embodiments of the present disclosure, the hydroxyl protecting group is selected from trityl (Tr group), 4-methoxytrityl (MMTr group), 4,4'-dimethoxytrityl (DMTr group) or 4,4',4"-trimethoxytriphenyl (TMTr group).

[0053] In some specific embodiments of the present disclosure, the hydroxyl protecting group is selected from 4,4'-dimethoxytrityl (DMTr group).

[0054] In the disclosure, "reactive phosphorus group" refers to a phosphorus-containing group that can react with other compounds to be removed.

[0055] In some optional embodiments of the present disclosure, the reactive phosphorus group is selected from

[0056] In some specific embodiments of the present disclosure, the reactive phosphorus group is selected from

[0057] In some optional embodiments of the present disclosure, the pharmaceutically active molecule is selected from small molecule drugs, antibodies or oligonucleotides.

[0058] In some optional embodiments of the present disclosure, the oligonucleotide is selected from a single-stranded oligonucleotide and a double-stranded oligonucleotide.

[0059] In some optional embodiments of the present disclosure, the pharmaceutically active molecule is selected from single-stranded oligonucleotides;

[0060] In some optional embodiments of the present disclosure, the single-stranded oligonucleotide is selected from antisense oligonucleotides (ASOs).

[0061] In some specific embodiments of the present disclosure, the pharmaceutically active molecule is selected from double-stranded oligonucleotides.

[0062] In some optional embodiments of the present disclosure, the double-stranded oligonucleotide is selected from small interfering RNA (siRNA).

[0063] In some specific embodiments of the present disclosure, the pharmaceutically active molecule is selected from siRNA.

[0064] In some specific embodiments of the present disclosure, the siRNA is conjugated to one of the compounds, and one of the compounds is conjugated to the 3' end of the sense strand of the siRNA.

[0065] In some optional embodiments of the present disclosure, the siRNA is conjugated to one of the compounds, and one of the compounds is conjugated to the 5' end of the sense strand of the siRNA.

[0066] In some specific embodiments of the present disclosure, the siRNA is conjugated to two of the compounds, and the two compounds are conjugated to the 3' end and the 5' end of the sense strand of the siRNA, respectively.

[0067] In some optional embodiments of the present disclosure, the solid phase carrier is selected from a resin containing an amino functional group or a controlled pore glass bead containing an amino functional group.

[0068] In some optional embodiments of the present disclosure, R 2b Selected from It represents resin (for example, polystyrene resin PS) or controlled pore glass beads (CPG).

[0069] In some specific embodiments of the present disclosure, R 2a Selected from

[0070] In some specific embodiments of the present disclosure, Selected from

[0071] In some optional embodiments of the present disclosure, j is selected from 0, 1 or 2.

[0072] In some specific embodiments of the present disclosure, j is selected from 0.

[0073] In some specific embodiments of the present disclosure, j is selected from 1.

[0074] In some specific embodiments of the present disclosure, j is selected from 2.

[0075] In some optional embodiments of the present disclosure, in formula (Ia), each Cy is independently selected from any of the following structures:

[0076]

[0077] In some specific embodiments of the present disclosure, the compound is selected from any of the following structures:

[0078]

[0079]

[0080] In some specific embodiments of the present disclosure, the compound is selected from any one of the following compounds:

[0081]

[0082]

[0083]

[0084]

[0085]

[0086]

[0087]

[0088]

[0089]

[0090]

[0091]

[0092]

[0093]

[0094]

[0095]

[0096] In the second aspect of the present disclosure, the present disclosure also provides a conjugate having a structure represented by formula (Ib) or a stereoisomer thereof, a pharmaceutically acceptable salt or a prodrug thereof:

[0097]

[0098] In formula (Ib), Nu represents an oligonucleotide;

[0099] The k is selected from 1 or 2;

[0100] The structural formula of Q is Wherein, said j' is selected from 1, 2, 3 or 4;

[0101] The *, M, p, q, and Cy are as defined above.

[0102] In some optional embodiments of the present disclosure, j' is selected from 1, 2 or 3.

[0103] In some specific embodiments of the present disclosure, the j' is selected from 1.

[0104] In some specific embodiments of the present disclosure, said j' is selected from 2.

[0105] In some specific embodiments of the present disclosure, said j' is selected from 3.

[0106] In some specific embodiments of the present disclosure, k is selected from 1.

[0107] In some specific embodiments of the present disclosure, k is selected from 2.

[0108] In some optional embodiments of the present disclosure, the oligonucleotide is selected from a single-stranded oligonucleotide or a double-stranded oligonucleotide.

[0109] In some optional embodiments of the present disclosure, the oligonucleotide is selected from single-stranded oligonucleotides. The single-stranded oligonucleotides include, but are not limited to, antisense oligonucleotides (ASO), aptamers, ribozymes, deoxyribozymes, circular RNA (circRNA), etc.

[0110] In some optional embodiments of the present disclosure, the single-stranded oligonucleotide is selected from ASO.

[0111] In some specific embodiments of the present disclosure, the oligonucleotide is selected from a double-stranded oligonucleotide. The double-stranded oligonucleotide includes but is not limited to: small interfering RNA (siRNA), double-stranded RNA (dsRNA), microRNA (miRNA), small guide RNA (sgRNA), small activating RNA (saRNA) and short hairpin RNA (shRNA).

[0112] In some specific embodiments of the present disclosure, the double-stranded oligonucleotide is selected from siRNA.

[0113] In some specific embodiments of the present disclosure, the Nu represents a double-stranded oligonucleotide.

[0114] In some specific embodiments of the present disclosure, the Nu represents siRNA.

[0115] In some specific embodiments of the present disclosure, the k is selected from 1, and one Q is conjugated to the 3' end of the siRNA sense strand.

[0116] In some optional embodiments of the present disclosure, the k is selected from 1, and one Q is conjugated to the 5' end of the siRNA sense strand.

[0117] In some specific embodiments of the present disclosure, the k is selected from 2, and the two Qs are conjugated to the 3' end and the 5' end of the siRNA sense strand, respectively. In some optional embodiments of the present disclosure, the conjugate is selected from any of the following structures:

[0118]

[0119] In some specific embodiments of the present disclosure, the conjugate is selected from any one of the following compounds:

[0120]

[0121]

[0122]

[0123]

[0124]

[0125] In the third aspect of the present disclosure, the present disclosure further provides a composition, which comprises the conjugate according to the second aspect.

[0126] In some optional embodiments of the present disclosure, the composition further comprises optionally one or more pharmaceutically acceptable carriers or excipients.

[0127] In the fourth aspect of the present disclosure, the present disclosure further provides the use of any of the following items in the preparation of a medicament for preventing and / or treating a disease:

[0128] (I), the compound described in the first aspect; and / or

[0129] (II), the conjugate according to the second aspect; and / or

[0130] (III) The composition described in the third aspect.

[0131] In some embodiments of the present disclosure, the disease is selected from pathological conditions or diseases caused by abnormal expression of specific genes in target cells.

[0132] In some embodiments of the present disclosure, the disease is selected from a liver-related disease.

[0133] In a fifth aspect of the present disclosure, the present disclosure further provides use of any of the following items in the preparation of a drug for reducing target gene expression or activity.

[0134] (I), the compound described in the first aspect; and / or

[0135] (II), the conjugate according to the second aspect; and / or

[0136] (III) The composition described in the third aspect.

[0137] In a sixth aspect of the present disclosure, the present disclosure further provides a drug, comprising any of the following items and a pharmaceutically acceptable excipient or adjuvant:

[0138] (I), the compound described in the first aspect; and / or

[0139] (II), the conjugate according to the second aspect; and / or

[0140] (III) The composition described in the third aspect.

[0141] In the seventh aspect of the present disclosure, the present disclosure also provides a drug combination, comprising the drug described in the sixth aspect and any other effective ingredients.

[0142] In an eighth aspect of the present disclosure, the present disclosure also provides a method for treating and / or preventing a disease in a subject, comprising administering to the subject a pharmaceutically acceptable amount of any of the following:

[0143] (I), the conjugate described in the second aspect; and / or

[0144] (II), the composition of the third aspect; and / or

[0145] (III) the drug described in the sixth aspect; and / or

[0146] (IV) The drug combination described in the sixth aspect.

[0147] In some specific embodiments of the present disclosure, the disease is selected from pathological conditions or diseases caused by abnormal expression of specific genes in target cells.

[0148] In the ninth aspect of the present disclosure, the present disclosure also provides a method for reducing the expression or activity of a target gene, which comprises contacting any of the following items with a cell:

[0149] (I), the conjugate described in the second aspect; and / or

[0150] (II), the composition of the third aspect; and / or

[0151] (III) the drug described in the sixth aspect; and / or

[0152] (IV) The drug combination described in the seventh aspect.

[0153] Beneficial effects of the present disclosure:

[0154] The present disclosure provides GalNAc compounds, conjugates, compositions and their uses. The present disclosure obtains the oligonucleotide conjugate provided by the present disclosure by conjugating the compound provided by the present disclosure to a specific oligonucleotide (e.g., siRNA), and the compound can highly effectively target the oligonucleotide conjugate to liver cells and effectively inhibit the expression of target genes in liver cells, and can be used to treat and / or prevent pathological conditions or diseases caused by abnormal expression of target genes in liver cells, and has higher in vivo activity than control vectors, more stable and lasting pharmacodynamic effects, and is expected to have excellent safety and low animal level toxicity. BRIEF DESCRIPTION OF THE DRAWINGS

[0155] In order to more clearly illustrate the embodiments of the present disclosure or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0156] Figure 1 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 1 is shown in Example 1;

[0157] Figure 2 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 2 is shown in Example 2;

[0158] Figure 3 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 3 is shown in Example 3;

[0159] Figure 4 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 4 is shown in Example 4;

[0160] Figure 5 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 5 is shown in Example 5;

[0161] Figure 6 The relative expression levels of the target genes in mice after administration of the siRNA conjugate described in Example 6 are shown in Example 6;

[0162] Figure 7 The relative expression levels of the target genes in mice after administration of the siRNA conjugate described in Example 7 are shown in Example 7;

[0163] Figure 8 The relative expression levels of the target genes in mice after administration of the siRNA conjugate described in Example 8 are shown in Example 8;

[0164] Fig. 9The relative expression levels of the target genes in mice after administration of the siRNA conjugate described in Example 9 are shown;

[0165] Fig.10 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 10 in Example 10 is shown;

[0166] Fig.11 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 11 is shown in Example 11;

[0167] Fig.12 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 12 in Example 12 is shown;

[0168] Fig.13 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 13 in Example 13 is shown;

[0169] Fig.14 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 14 in Example 14 is shown;

[0170] Fig.15 The relative expression level of the target gene in mice after administration of the siRNA conjugate described in Example 15 in Example 15 is shown;

[0171] Fig.16a The AST in the blood of each group of animals is detected after the siRNA conjugate described in Example 16 is administered in Example 16;

[0172] Fig.16b The following is a diagram showing the detection of ALT in the blood of each group of animals after administration of the siRNA conjugate described in Example 16;

[0173] Fig.16c The TBIL in the blood of each group of animals is detected after the siRNA conjugate described in Example 16 is administered in Example 16;

[0174] Fig.16d The detection of Urea in the blood of each group of animals after administration of the siRNA conjugate described in Example 16 is shown in Example 16;

[0175] Fig.16e The figure shows the detection of Crea in the blood of each group of animals after the siRNA conjugate described in Example 16 is administered;

[0176] Fig.16fThe following is a diagram showing the detection of TC in the blood of each group of animals after administration of the siRNA conjugate described in Example 16;

[0177] Figure 16g The following is a diagram showing the detection of TG in the blood of each group of animals after administration of the siRNA conjugate described in Example 16;

[0178] Figure 16h The detection of WBC in the blood of each group of animals after the administration of the siRNA conjugate described in Example 16 is shown in Example 16;

[0179] Fig.16i The NEUT in the blood of each group of animals is detected after the siRNA conjugate described in Example 16 is administered in Example 16;

[0180] Fig.16j Detection of LYMPH in the blood of each group of animals after administration of the siRNA conjugate described in Example 16;

[0181] Figure 16k After the siRNA conjugate described in Example 16 was administered, the liver tissues of the animals in each group were subjected to histopathological examination. DETAILED DESCRIPTION

[0182] The present disclosure discloses compounds, conjugates, compositions and their uses. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve them. It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all deemed to be included in the present disclosure. The methods and applications of the present disclosure have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present disclosure to implement and apply the disclosed technology.

[0183] The affinity of ASGPR to ligand is mainly affected by the following factors:

[0184] a. Type of ligand terminal sugar molecules. Ligand molecules with Gal or GalNAc at the end can be recognized by ASGPR. The affinity of GalNAc binding to ASGPR is 10 to 50 times higher than that of Gal. Moreover, GalNAc ligand molecules are more likely to escape the recognition of Kupffer cells and target more hepatic parenchymal cells.

[0185] b. Sugar molecule substitution site: 1-OH, 2-OH (or 2-amino), 3-OH, 4-OH and 5-CH2- on Gal (or GalNAc) are all involved in the binding of ASGPR receptors; when 5-CH2- is connected to a negatively charged group or 4-OH, 3-OH, 2-OH (or 2-amino) is replaced, the affinity with the receptor drops sharply; when 1-OH is glycosylated and replaced, when the glycosidic bond is in the α conformation, the affinity with the receptor is weakened, and when it is in the β conformation and the substituent is a straight chain structure, the affinity is not affected; only 6-OH does not participate in receptor binding and points to the solvent region, so it is suitable as a connection site to connect with carriers, drugs, etc.

[0186] c. Spatial distance between the terminal sugar group and the carrier: ASGPR can effectively recognize sugar groups when there are at least 6 CH2 units between the sugar group and the carrier.

[0187] In addition, different molecular cluster structures of ligands and different connection methods with oligonucleotides will significantly affect the activity of oligonucleotides in vivo. Higher activity means better therapeutic effects or lower dosages. Under the same efficacy, lower dosages also mean lower toxic reactions.

[0188] Based on the affinity characteristics of the ASGPR receptor mentioned above, we designed a ligand with high affinity for ASGPR to achieve liver-targeted delivery of drugs or genes to achieve the purpose of regulating target gene expression.

[0189] Explanation of terms

[0190] The term "aliphatic ring" refers to a structure having a cyclic carbon skeleton. The term "5- to 8-membered aliphatic ring" refers to a monocyclic structure having 5 to 8 carbon atoms in the cyclic carbon skeleton. The term "saturated aliphatic ring" refers to a cyclic carbon skeleton composed entirely of carbon-carbon single bonds.

[0191] The term "5- to 8-membered heterocyclic aliphatic ring" means that one or more carbon atoms on the aliphatic ring are replaced by heteroatoms. The term "saturated heterocyclic aliphatic ring" means that one or more carbon atoms on the saturated aliphatic ring are replaced by heteroatoms.

[0192] The term "alkyl" refers to a radical of the formula The term "C1-C6 alkyl" refers to an alkyl group having 1 to 6 carbon atoms.

[0193] The term "alkylene" refers to a group of the general formula The chain alkylene group may be a straight chain alkylene group or a branched chain alkylene group.

[0194] The term "CH2CH2" refers to a C2 straight chain alkyl group (ie, ethylene), having the structural formula:

[0195] The term "alkoxy" refers to

[0196] The term "alkanoyl" refers to For example, "C1-C6 chain alkyl acyl" can be formyl, acetyl, propionyl, n-butyryl or isobutyryl, etc.

[0197] The term "NH" refers to an imino group, having the structural formula

[0198] The term "CO" refers to a carbonyl group, which has the structural formula

[0199] The term "CN" refers to a cyano group, with the structural formula

[0200] The structural formula of the term "triazole" is

[0201] In the context of the present disclosure, "pharmaceutically acceptable salts" include pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0202] In the context of the present disclosure, "pharmaceutically acceptable acid addition salts" refer to salts formed with inorganic or organic acids that retain the biological effectiveness of free bases without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, and the like; organic acid salts include, but are not limited to, formates, acetates, 2,2-dichloroacetates, trifluoroacetates, propionates, caproates, caprylates, decanoates, undecylenates, glycolates, gluconates, lactates, sebacates, adipates, glutarates, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamates, pyroglutamates, aspartates, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginate, ascorbates, salicylates, 4-aminosalicylates, naphthalene disulfonates, and the like. These salts can be prepared by methods known in the art.

[0203] In the context of the present disclosure, "pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or an organic base that can maintain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, etc. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts and magnesium salts, preferably sodium salts. The salt derived from organic base includes but is not limited to the following salt: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the art.

[0204] In the context of the present disclosure, "oligonucleotide" is a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), generally consisting of 10-50 nucleotides. Oligonucleotides can regulate gene expression through a series of processes such as RNA interference, ribonuclease-mediated target degradation, splicing regulation, non-coding RNA inhibition, gene activation and programmed gene editing.

[0205] the term Indicates the site where a group is attached via a covalent bond.

[0206] In the structural formula of the compound or ligand disclosed herein, the bond "-" indicates that the configuration is not specified. If chiral isomerism exists in the chemical structure, the bond "-" can be or include both and Although all of the above structural formulae are drawn in certain isomeric forms for simplicity, the present disclosure may include all isomers, for example, tautomers, rotational isomers, geometric isomers, diastereomers, racemates, and enantiomers.

[0207] In the structural formula of the compound or ligand disclosed in the present invention, the bond Indicates that the configuration is not specified. If there are cis-trans isomers in the chemical structure, the bond The configuration can be E-type, Z-type, or both E and Z configurations.

[0208] Unless otherwise indicated, the following definitions used herein shall apply. For purposes of this disclosure, chemical elements are consistent with the Periodic Table of the Elements, CAS version, and Handbook of Chemistry and Physics, 75th edition, 1994. In addition, general principles of organic chemistry can be found in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry" by Michael B. Smith and Jerry March, John Wiley & Sons, New York: 2007, the entire contents of which are incorporated herein by reference.

[0209] Unless otherwise specified or there is a clear conflict in context, the articles "a", "an", and "the" as used herein are intended to include "at least one" or "one or more". Therefore, these articles as used herein refer to articles that refer to one or more than one (i.e., at least one) of the objects. For example, "a component" refers to one or more components, i.e., there may be more than one component contemplated for use or use in the implementation of the described embodiment.

[0210] The term "comprising" is an open expression, that is, including the contents specified in the present disclosure but not excluding other contents.

[0211] "Stereoisomers" refer to compounds that have the same chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like.

[0212] "Chiral" refers to a molecule that is non-superimposable on its mirror image; "achiral" refers to a molecule that is superimposable on its mirror image.

[0213] "Enantiomers" refer to two non-superimposable isomers of a compound that are mirror images of each other.

[0214] "Diastereoisomers" refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Diastereomeric mixtures can be separated by high resolution analytical procedures such as electrophoresis and chromatography, for example HPLC.

[0215] The stereochemical definitions and conventions used in this disclosure generally follow SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994.

[0216] As described in the present disclosure, the compounds of the present disclosure may be optionally substituted with one or more substituents, such as the above general formula compounds, or as specific examples in the embodiments, subclasses, and classes of compounds encompassed by the present disclosure.

[0217] In general, the term "substituted" means that one or more hydrogen atoms in a given structure are replaced by a specified substituent. Unless otherwise indicated, a substituted group may have a substituent at each substitutable position of the group. When more than one position in a given structure can be substituted by one or more substituents selected from a specified group, then the substituents may be the same or different at each substitutable position.

[0218] The term "unsubstituted" means that the designated group bears no substituents.

[0219] The term "optionally substituted with" can be used interchangeably with the term "unsubstituted or substituted with", i.e., the structure is unsubstituted or substituted with one or more substituents disclosed herein. Substituents disclosed herein include, but are not limited to, D, F, Cl, Br, I, N3, CN, NO2, OH, SH, NH2, alkyl, haloalkyl, haloalkoxy, haloalkylamino, alkenyl, alkynyl, alkoxy, alkylamino, cycloalkyl, heterocyclyl, aryl, heteroaryl, and the like.

[0220] In addition, it should be noted that, unless otherwise explicitly stated, the description methods used in this disclosure, "each ... is independently" and "... are each independently" and "... are independently" can be interchanged, and should be understood in a broad sense, which can mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other. Taking R3 as an example, the specific options of R3 between the structural formula "C1-C50 alkylene optionally substituted by R3" and the structural formula "-C(O)-NH-C1-50 alkylene optionally substituted by R3" do not affect each other.

[0221] The term "small interfering RNA (siRNA)" refers to a type of double-stranded RNA, comprising a sense strand and an antisense strand, each of which is 17 to 30 nucleotides in length. siRNA mediates the targeted cleavage of RNA transcripts in the RISC pathway by forming a silencing complex (RISC). Specifically, siRNA guides the specific degradation of mRNA sequences through the known RNA interference (RNAi) process, inhibiting the translation of mRNA into amino acids and proteins.

[0222] In the context of the present disclosure, the term "antisense strand (or guide strand)" includes a region that is substantially complementary to a target sequence. "Sense strand (or follower strand)" refers to an iRNA strand that contains a region that is substantially complementary to the antisense strand. The term "substantially complementary" refers to complete complementarity or at least partial complementarity, for example, the antisense strand is completely complementary to the target sequence or at least partially complementary. In the case of partial complementarity, mismatches can exist in the interior or terminal regions of the molecule, wherein the most tolerated mismatches exist in the terminal regions, for example, within 5, 4, 3 or 2 nucleotides of the 5'- and / or 3'-end of the iRNA.

[0223] It should be noted that "at least a portion of the antisense strand is substantially complementary to the mRNA" means that the antisense strand has a polynucleotide that is substantially complementary to a continuous portion of the mRNA of interest.

[0224] In the context of the present disclosure, "oligonucleotide" is a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), generally consisting of 10 to 50 nucleotides. Oligonucleotides can regulate gene expression through a series of processes such as RNA interference, ribonuclease-mediated target degradation, splicing regulation, non-coding RNA inhibition, gene activation and programmed gene editing.

[0225] In the context of the present disclosure, "antisense oligonucleotides (ASO)" is a single-stranded oligonucleotide molecule, generally composed of 10 to 50 nucleotides. After entering the cell, ASO binds to its complementary target mRNA through the principle of base complementary pairing under the action of ribonuclease H1, thereby inhibiting the expression of the target gene.

[0226] In the context of the present disclosure, unless otherwise specified, capital letters A, U, G, C, and T represent the base composition of nucleotides; a lowercase letter m represents that the nucleotide adjacent to the left of the letter m is a 2'-methoxy-modified nucleotide; a lowercase letter f represents that the nucleotide adjacent to the left of the letter f is a 2'-fluoro-modified nucleotide; and a lowercase letter s represents that the two nucleotides adjacent to the left and right of the letter s are connected by a phosphorothioate bond.

[0227] In the context of the present disclosure, the term "pharmaceutically acceptable carrier" includes any solvent, dispersion medium, coating material, surfactant, antioxidant, preservative (e.g., antibacterial agent, antifungal agent), isotonic agent, salt, drug stabilizer, binder, excipient, dispersant, lubricant, sweetener, flavoring agent, colorant, or a combination thereof, which are known to those skilled in the art (such as Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except for the case where any conventional carrier is incompatible with the active ingredient, its use in treatment or pharmaceutical composition is covered.

[0228] In the context of the present disclosure, the term "pharmaceutically acceptable excipient" may include any solvent, solid excipient, diluent or other liquid excipient, etc., suitable for a particular target dosage form. Except for any conventional excipients that are incompatible with the siRNA of the present disclosure, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a harmful manner, their use is also within the scope of the present disclosure.

[0229] In the context of the present disclosure, "subject" refers to any animal, such as a mammal or marsupial. The subjects of the present disclosure include, but are not limited to, humans, non-human primates (e.g., monkeys), mice, pigs, horses, donkeys, cattle, sheep, and any kind of poultry.

[0230] In the context of this disclosure, "treating," "alleviating," or "amelioration" are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results, including but not limited to a therapeutic benefit. "Therapeutic benefit" means eradication or amelioration of the underlying disorder being treated. Here, a therapeutic benefit is obtained by eradication or amelioration of one or more physiological symptoms associated with the underlying disorder, such that an improvement is observed in the subject, although the subject may still be afflicted with the underlying disorder.

[0231] In the context of this disclosure, "prevention" and "prevention" are used interchangeably. These terms refer to an approach to obtaining a beneficial or desired result, including but not limited to a prophylactic benefit. To obtain a "prophylactic benefit," a conjugate, RNAi agent, or composition can be administered to a subject at risk for a particular disease, or to a subject reporting one or more physiological symptoms of a disease, even though a diagnosis of the disease may not have been made.

[0232] In the context of the present disclosure, unless otherwise stated, the reagent ratios described in the embodiments of the present disclosure are calculated on a volume basis (v / v).

[0233] 2. Preparation of compounds

[0234] The reagents and sources of the reagents used in the preparation of the compounds disclosed herein are as follows:

[0235] 1) Tributyltin hydride, CAS No. 688-73-3, purchased from Beijing Coupling Technology Co., Ltd.;

[0236] 2) Benzaldehyde dimethyl acetal, CAS No. 125-88-8, purchased from Beijing Coupling Technology Co., Ltd.;

[0237] 3) DL-10-camphorsulfonic acid, CAS No. 5872-08-2, purchased from Beijing Coupling Technology Co., Ltd.;

[0238] 4) 3-bromopropyne, CAS No. 106-96-7, purchased from Beijing Coupling Technology Co., Ltd.;

[0239] 5) 4,4'-bis(methoxytrityl) chloride (abbreviated as DMTrCl), CAS No. 40615-36-9, purchased from Beijing Coupling Technology Co., Ltd.;

[0240] 6) 4,5-Dicyanoimidazole (abbreviated as DCI), CAS No. 1122-28-7, purchased from Beijing Coupling Technology Co., Ltd.;

[0241] 7) Bis(diisopropylamino)(2-cyanoethoxy)phosphine, CAS No. 102691-36-1, purchased from Beijing Coupling Technology Co., Ltd.;

[0242] 8) 1-O-acetyl-2,3,5-O-tribenzoyl-BETA-L-ribofuranose, CAS No. 3080-30-6, purchased from Beijing Coupling Technology Co., Ltd.;

[0243] 9) triethylsilane, CAS No. 617-86-7, purchased from Beijing Coupling Technology Co., Ltd.;

[0244] 10) trimethylsilyl trifluoromethanesulfonate (abbreviated as TMSOTf), CAS No. 27607-77-8, purchased from Beijing Coupling Technology Co., Ltd.;

[0245] 11) Cesium carbonate, CAS No. 534-17-8, purchased from Beijing Coupling Technology Co., Ltd.;

[0246] 12) Silver oxide (Ag2O), CAS No. 20667-12-3, purchased from Beijing Coupling Technology Co., Ltd.;

[0247] 13) Potassium iodide (KI), CAS No. 7681-11-0, purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.;

[0248] 14) p-Toluenesulfonyl chloride (TsCl), CAS No. 98-59-9, purchased from Beijing Coupling Technology Co., Ltd.;

[0249] 15) Trimethylsilyl azide (TMSN3), CAS No. 4648-54-8, purchased from Beijing Coupling Technology Co., Ltd.;

[0250] 16) Potassium fluoride (KF), CAS No. 7789-23-3, purchased from Beijing Coupling Technology Co., Ltd.;

[0251] 17) N,N-dimethylformamide (DMF), CAS No. 68-12-2, purchased from Beijing Coupling Technology Co., Ltd.;

[0252] 18) D-galactosamine pentaacetate, CAS No. 76375-60-5, purchased from Beijing Coupling Technology Co., Ltd.;

[0253] 19) Scandium trifluoromethanesulfonate, CAS No. 144026-79-9, purchased from Beijing Coupling Technology Co., Ltd.;

[0254] 20) (S)-(+)-Glycerol acetone acetal, CAS No. 22323-82-6, purchased from Beijing Coupling Technology Co., Ltd.;

[0255] 21) Sodium hydride (NaH), CAS No. 7646-69-7, purchased from Beijing Coupling Technology Co., Ltd.;

[0256] 21) Amberlyst-15 (Chinese name: polymer of vinylbenzenesulfonic acid and divinylbenzene, English name: amberlyst 15 ion-exchange resin), CAS No. 39389-20-3, purchased from Beijing Coupling Technology Co., Ltd.;

[0257] 22) Aminoalkyl-CPG (model C3006-1000), purchased from Beijing Coupling Technology Co., Ltd.;

[0258] 23) Succinic anhydride, CAS No. 108-30-5, purchased from Beijing Coupling Technology Co., Ltd.

[0259] 24) Reference compound L96-PS

[0260] Compound L96-PS was purchased from Agilent Pharmaceuticals (Tianjin) Co., Ltd. with a loading of 120±12 μmol / g (detection method: UV / HPLC).

[0261] The structural formula of the reference compound L96-PS is as follows:

[0262]

[0263] Wherein, PS represents polystyrene resin solid phase carrier.

[0264] Unless otherwise stated, the reagents and consumables (Table 1) and instruments and equipment (Table 2) used in the present disclosure are all commercially available products from the following manufacturers.

[0265] Table 1 Main reagents and consumables

[0266]

[0267] Table 2 Main instruments and equipment

[0268]

[0269] The raw materials and reagents used in the GalNAc compounds, conjugates, compositions and uses thereof provided in the present disclosure can all be purchased from the market.

[0270] The present disclosure is further described below in conjunction with embodiments:

[0271] Preparation Example 1: Synthesis of Compound NM041

[0272] In this preparation example, the synthesis process of compound NM041 is as follows:

[0273]

[0274] (1-1) Synthesis of Compound NM041-2

[0275] Compound NM041-1 (25.0 g, 1.0 eq) was dissolved in 250 ml toluene, heated to 110°C, tributyltin hydride (17.7 g, 1.0 eq) and azobisisobutyronitrile (1 g, 0.1 eq) were added, and refluxed at 110°C for 2 hours. After the reaction was completed, the reaction solution was cooled to 25°C, ethyl acetate (100 ml) and potassium fluoride (10.59 g in 30 ml water, 3.0 eq) were added, stirred at 25°C for 2 hours, filtered and the organic phase was separated, the aqueous phase was washed twice with ethyl acetate (50 ml × 2), the organic phases were combined, 50 ml of saturated sodium chloride aqueous solution was added to the organic phase, washed once, anhydrous sodium sulfate was added to dry and filtered, and concentrated under reduced pressure to obtain compound NM041-2 (18.7 g, yield 87.9%) as a light yellow oil. MS ESI (m / z) = 333.1 [M+H] + .

[0276] (1-2) Synthesis of Compound NM041-3

[0277] Compound NM041-2 (18.7 g, 1 eq) was dissolved in 50 ml of anhydrous methanol, sodium methoxide (0.288 g, 0.1 eq) was added, and stirred at 25°C for 1 hour. After the reaction was completed, the pH of the reaction solution was adjusted to 6-7 with a 4 mol / L hydrogen chloride 1,4-dioxane solution under ice bath, concentrated, condensed twice with acetonitrile, and vacuum dried to obtain compound NM041-3 (9.4 g, yield 100%) as a white solid.

[0278] (1-3) Synthesis of Compound NM041-4

[0279] Compound NM041-3 (9.4 g, 1.0 eq) was dissolved in 150 ml of acetonitrile, and benzaldehyde dimethyl acetal (30 ml, 3 eq) and DL-10-camphorsulfonic acid (1.5 g, 0.1 eq) were added respectively, stirred at 25°C for 5 hours, 3 ml of triethylamine was added, and stirred at 25°C for 30 min. After the reaction was completed, the reaction solution was concentrated, 100 ml of water was added to the reaction solution, and extracted with ethyl acetate twice (100 ml×2), the organic phases were combined, dried over anhydrous sodium sulfate and filtered, concentrated under reduced pressure, and purified by column chromatography (eluent: ethyl acetate / petroleum ether=57 / 43, v / v) to obtain compound NM041-4 (8.6 g, yield 59.5%) as a white solid. MS ESI (m / z)=252.2[M+H] + .

[0280] (1-4) Synthesis of Compound NM041-5

[0281] Compound NM041-4 (4.3 g, 1.0 eq) was dissolved in 40 ml of N, N-dimethylformamide (DMF), sodium hydride (2.7 g, 68 mmol, 4 eq) was added under ice bath, reacted under ice bath for 30 minutes, 3-bromopropyne (8.1 g, 4 eq) was added, stirred at 25°C for 2 hours, and quenched by adding 20 ml of water. After the reaction, the reaction solution was extracted with ethyl acetate 3 times (50 ml × 3), the organic phases were combined, the organic phases were washed with saturated sodium chloride solution 5 times (20 ml × 5), the organic phases were dried with anhydrous sodium sulfate and filtered, and concentrated to obtain brown oily compound NM041-5 (yield 100%). MS ESI (m / z) = 329.2 [M + H] + .

[0282] (1-5) Synthesis of Compound NM041-6

[0283] Compound NM041-5 (5.6 g, 1.0 eq) was dissolved in 30 ml of dichloromethane (DCM), and 300 ml of 70 mass % acetic acid aqueous solution was added, and the mixture was reacted at 70°C for 1 hour. After the reaction, the reaction solution was directly concentrated to obtain a yellow oil compound NM041-6 (yield 100%). MS ESI (m / z) = 241 [M+H] + .

[0284] (1-6) Synthesis of Compound NM041-7

[0285] Compound NM041-6 (5.6 g, 1.0 eq) was dissolved in 50 ml of pyridine, 4,4'-dimethoxytriphenylmethane (10.2 g, 1.3 eq, abbreviated as DMTrCl) was added under ice bath, nitrogen was replaced 3 times, stirred at 25°C for 3 hours, and 50 ml of methanol was added to quench. After the reaction was completed, the reaction solution was concentrated, 50 ml of water was added, and ethyl acetate was extracted 3 times (50 ml×3), the organic phases were combined, dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (eluent: ethyl acetate / petroleum ether=16 / 84, v / v) to obtain compound NM041-7 (5 g, yield 39.6%) as a light yellow solid. MS ESI (m / z)=543.1[M+H] + .

[0286] (1-7) Synthesis of Compound NM041

[0287] Compound NM041-7 (2.0 g, 1.5 eq) was dissolved in 20 ml of anhydrous dichloromethane, and DCI (347.4 mg, 0.8 eq) and bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.22 g, 1.1 eq) were added respectively, and the atmosphere was replaced with nitrogen three times, and stirred at 25°C for 2 hours. After the reaction was completed, 20 ml of saturated sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted with dichloromethane three times (20 ml×3), and the organic phases were combined, dried with anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water=72 / 28, v / v), and vacuum dried for 12 hours to obtain compound NM041 (2 g, yield 73.09%) as a white powder. MS ESI (m / z)=743.2[M+H] + .

[0288] 1 H NMR(400MHz, Acetonitrile-d3)δ7.53–7.47(m,2H),7.36(tt,J=9.6,3.4Hz,6H),7.28–7.22(m,1H),6.94–6 .86(m,4H),4.45(d,J=2.4Hz,1H),4.35(dt,J=6.1,1.9Hz,2H),4.18(ddd,J=11.2,5.4,2.6Hz,1H),3.81(s,7 H),3.79–3.20(m,8H),3.07(dt,J=10.5,7.0Hz,1H),2.79(q,J=2.6Hz,1H),2.72(dt,J=5.1,2.4Hz,1H),2.69 –2.63(m,1H),2.48–2.34(m,1H),2.17(d,J=1.0Hz,2H),1.08(dd,J=6.8,4.1Hz,10H),0.90(d,J=6.8Hz,2H).

[0289] Preparation Example 2: Synthesis of Reference Compound NM042

[0290] In this preparation example, the synthesis process of compound NM042 is as follows:

[0291]

[0292] (2-1) Synthesis of Compound NM042-2

[0293] Compound NM042-1 (5.0 g, 1.0 eq.) and sodium hydride (3.78 g, 2.5 eq.) were added to 60 ml of DMF, cooled to 0°C, stirred at 0°C for 0.5 hours, and propargyl bromide (9.0 g, 2.0 eq.) was slowly added during stirring, and stirred at 25°C for 4 hours. After the reaction was completed, 100 ml of water was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (3×100 ml), the organic phases were combined, washed once with 100 ml of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain oily compound NM042-2 (9.0 g). ESI-MS (m / z) = 171 [M+H] + .

[0294] (2-2) Synthesis of Compound NM042-3

[0295] Compound NM042-2 (9.0 g, 37.8 mmol) and Amberlyst-15 resin (13.5 g, 150% w / w) were added to 180 ml of methanol, replaced with nitrogen three times, and stirred at 25°C for 6 hours. After the reaction was completed, the reaction solution was filtered and concentrated to obtain an oily compound NM042-3 (9.1 g). ESI-MS (m / z) = 131.2 [M+H] + .

[0296] (2-3) Synthesis of Compound NM042-4

[0297] Compound NM042-3 (5 g, 1.0 eq.) was added to 75 ml of pyridine solution, cooled to 0°C, DMTrCl (16.9 g, 1.69 eq.) was added in batches at 0°C, and stirred at 25°C for 3 hours. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography (C18 column, eluent: acetonitrile / water = 72 / 28, v / v) to obtain compound NM042-4 (15 g, yield 90.4%). ESI-MS (m / z) = 433.2 [M+H] + .

[0298] (2-4) Synthesis of Compound NM042

[0299] Compound NM042-4 (2.5 g, 1.0 eq.), bis(diisopropylamino)(2-cyanoethoxy)phosphine (3.5 g, 2.0 eq.), and DCI (0.567 g, 0.8 eq.) were added to 50 ml of DCM and stirred for 3 hours under nitrogen protection. After the reaction was completed, 50 ml of saturated sodium bicarbonate solution was added to the reaction solution for washing once, and the organic phase was separated. The organic phase was washed once with 50 ml of saturated brine, dried with anhydrous sodium sulfate, filtered, concentrated, and separated by reverse phase HPLC to obtain compound NM042 (2.0 g, yield 56%) as a white oil. ESI-MS (m / z): 619.3 [M+H] + .

[0300] 1 H NMR (400MHz, DMSO-d6) δ0.97–1.04 (d, J=6.7Hz, 3H), 1.06–1.20 (m, 9H), 3.05–3. 14(dd,J=5.5,10.7Hz,2H),3.46–3.69(m,6H),3.70–3.75(d,J=2.5Hz,7H),3.98–

[0301] 4.09(dt,J=4.9,10.3Hz,1H),4.09–4.17(m,2H),6.81–6.93(m,4H),7.15–7.34(m,7H),7.35–7.46(m,2H).

[0302] Preparation Example 3: Synthesis of Compound NM014 and Compound NM014A

[0303] In this preparation example, the synthesis process of compound NM014 and compound NM014A is as follows:

[0304]

[0305] (3-1) Synthesis of Compound NM014-2

[0306] Compound NM014-1 (50 g, 1.0 eq.) was added to 100 ml of ACN, nitrogen was replaced, the temperature was lowered to 0°C, TMSOTf (44.0 g, 2.0 eq.) was first added dropwise at 0°C, and then triethylsilane (34.5 g, 3.0 eq.) was added dropwise, the temperature was slowly raised to 25°C, and the reaction was carried out at 25°C for 12 hours. After the reaction was completed, 200 ml of purified water was added to the reaction solution, and the mixture was extracted twice with 200 ml of ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (eluent: n-heptane / ethyl acetate = 4 / 1, v / v) to obtain compound NM014-2 (41 g, yield 93.1%). ESI-MS (m / z) = 445.3 [M+H] + .

[0307] (3-2) Synthesis of Compound NM014-3

[0308] Compound NM014-2 (41 g, 1.0 eq.) was added to 410 ml of monomethylamine methanol and reacted at 25°C for 12 hours. After the reaction was completed, the reaction solution was directly concentrated and purified by column chromatography (eluent: first use dichloromethane / methanol = 10 / 1 to remove impurities; then use dichloromethane / methanol = 5 / 1, v / v) to obtain compound NM014-3 (7.5 g, yield 60.6%). ESI-MS (m / z) = 135.2 [M+H] + .

[0309] (3-3) Synthesis of Compound NM014-4

[0310] Compound NM014-3 (5.16 g, 1.0 eq.) was added to 30 ml of pyridine, cooled to 0°C, DMTrCl (14.32 g, 1.1 eq.) was added in batches at 0°C, stirred at 25°C for 6 hours, and quenched by adding 10 ml of methanol. After the reaction was completed, the reaction solution was directly concentrated, diluted with 50 ml of ethyl acetate, washed once with 30 ml of saturated sodium bicarbonate, washed twice with 30 ml of purified water, the organic phase was separated, concentrated, and purified by column chromatography (n-heptane / ethyl acetate = 5 / 1 to n-heptane / ethyl acetate = 1 / 1 gradient elution, v / v) to obtain compound NM014-4 (9.0 g, yield 53.6%). ESI-MS (m / z) = 437.3 [M+H] + .

[0311] (3-4) Synthesis of Compounds NM014-5 and NM014-5A

[0312] Dissolve compound NM014-4 (9.0 g, 1.0 eq.) in 90 ml of DMF, add cesium carbonate (7.4 g, 1.1 eq.), stir at 25°C for 10 min, cool to 0°C, add propargyl bromide (2.5 g, 1.0 eq.) dropwise at 0°C, after the addition is complete, slowly heat to 25°C, and react at 25°C for 16 hours. After the reaction was completed, 100 ml of ethyl acetate was added to the reaction solution, and the mixture was washed three times with 10 ml of purified water (10 ml×3). The organic phase was separated, dried over anhydrous sodium sulfate and filtered, and the organic phase was concentrated and purified by column chromatography (eluent: n-heptane / ethyl acetate = 5 / 1, v / v, first remove impurities, and then keep the polarity unchanged) to obtain the front peak compound NM014-5 (2.7 g, yield 27.6%) and the rear peak compound NM014-5A (2.3 g, yield 23.7%). Among them, the ESI-MS (m / z) of the front peak product compound NM014-5 = 475.4 [M+H] + , ESI-MS (m / z) of the latter peak compound NM014-5A = 475.4 [M+H] + .

[0313] (3-5) Synthesis of Compound NM014

[0314] The former peak compound NM014-5 (2.57 g, 1.0 eq.) was added to 26 ml of dichloromethane, and stirred continuously. DCI (0.83 g, 1.3 eq.) was added, and the atmosphere was replaced with nitrogen. At this time, the reaction system was white and turbid. The temperature was lowered to 0°C, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (2.44 g, 1.5 eq.) was added dropwise at 0°C. After the addition was completed, the temperature was slowly raised to 25°C, and stirred at 25°C for 3 hours. After the reaction was completed, the reaction system was diluted with 50 ml of dichloromethane, and the organic phase was washed once with 20 ml of saturated sodium bicarbonate, dried with anhydrous sodium sulfate and filtered. The organic phase was concentrated and purified by column chromatography (eluent: n-heptane / 0.1% by volume triethylamine in ethyl acetate = 4 / 1, v / v) to obtain compound NM014 (907 mg). ESI-MS (m / z) = 698.2 [M+Na] + .

[0315] 1H NMR(400MHz, DMSO-d6)δ0.88–0.94(d,J=6.8Hz,4H),1.05–1.14(m,8H),1.11–1.22(m,1H),1.18–1.26(m,1H),2.52–2.60(t ,J=5.9Hz,1H),2.72–2.80(m,1H),2.89–3.00(td,J=5.1,10.7Hz,1H),3.15–3.28(ddd,J=2.8,10.2,23.1Hz,1H),3.41–3.59 (m,4H),3.71–3.78(d,J=2.0Hz,6H),3.75–3.84(m,1H),3.88–3.99(dq,J=2.7,18.2Hz,1H),3.99–4.07(m,1H),4.14–4.21( m,1H),4.18–4.30(m,1H),4.27–4.38(m,1H),6.84–6.93(m,4H),7.17–7.35(m,7H),7.36–7.44(ddd,J=1.3,4.0,8.2Hz,2H).

[0316] (3-6) Synthesis of Compound NM014A

[0317] The late peak compound NM014-5A (2.3 g, 1.0 eq.) was added to 23 ml of dichloromethane, and stirred continuously. DCI (0.74 g, 1.3 eq.) was added and replaced with nitrogen. At this time, the reaction system was white and turbid. The temperature was lowered to 0°C. Bis(diisopropylamino)(2-cyanoethoxy)phosphine (2.19 g, 1.5 eq.) was added dropwise at 0°C. After the addition was completed, the temperature was slowly raised to 25°C and stirred at 25°C for 3 hours. After the reaction was completed, the reaction system was diluted with 50 ml of dichloromethane, the organic phase was washed once with 20 ml of saturated sodium bicarbonate, dried with anhydrous sodium sulfate and filtered, the organic phase was concentrated, and the normal phase was purified by column chromatography (eluent: n-heptane / 0.1 volume % triethylamine ethyl acetate solution = 4 / 1, v / v) to obtain compound NM014A (520 mg). ESI-MS (m / z) = 698.2 [M+Na] + .

[0318] 1H NMR (400MHz, DMSO-d6) δ1.10–1.20 (dd, J=6.7, 8.6Hz, 12H), 2.74–2.82 (m, 2H), 2.96–3.04 (dd, J=4.4, 10. 2Hz, 1H), 3.11–3.19 (dd, J=3.3, 10.2Hz, 1H), 3.38–3.43 (q, J=2.3Hz, 1H), 3.55–3.66 (m, 2H), 3.71–3.75 ( s,6H),3.75–3.85(m,3H),3.85–3.94(m,1H),4.01–4.07(dd,J=4.4,9.4Hz,1H),4.09–4.20(m,2H),4.22– 4.31(m,1H),4.43–4.52(dq,J=4.1,12.0Hz,1H),6.86–6.93(m,4H),7.19–7.35(m,7H),7.38–7.43(m,2H).

[0319] Preparation Example 4: Synthesis of Compound NM043

[0320] In this preparation example, the synthesis process of compound NM043 is as follows:

[0321]

[0322] (4-1) Synthesis of Compound NM043-2

[0323] Compound NM043-1 (10 g, 1.0 eq.), silver oxide (23.16 g, 1.5 eq.), potassium iodide (12.16 g, 1.1 eq.) were added to 100 ml of dichloromethane, cooled to 0°C, and a dichloromethane (100 ml) solution of TsCl (12.7 g, 1.0 eq.) was slowly added, and stirred at 25°C for 2 hours. After the reaction was completed, the reaction solution was filtered, and the organic phase was washed twice with 100 ml of water, once with 100 ml of saturated sodium chloride water, dried with anhydrous sodium sulfate, filtered, and concentrated to obtain an oily compound NM043-2 (12.0 g). ESI-MS (m / z) = 305.1 [M+H] + .

[0324] (4-2) Synthesis of Compound NM043-3

[0325] Compound NM043-2 (12.0 g, 1.0 eq), TMSN3 (azidotrimethylsilane, CAS No. 4648-54-8, 13.62 g, 3.0 eq.), potassium fluoride (6.9 g, 3.0 eq.) were added to 72 ml of DMF, replaced with nitrogen three times, heated to 60°C, and stirred at 60°C for 1.5 hours. After the reaction was completed, the temperature was lowered to 25°C, 100 ml of water was added to the reaction solution, and extracted three times with 60 ml of ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water = 72 / 28, v / v) to obtain oily compound NM043-3 (3 g). ESI-MS (m / z) = 176.3 [M+H] + .

[0326] (4-3) Synthesis of Compound NM043

[0327] Compound NM043-3 (3.0 g, 1.01 eq.) and D-galactosamine pentaacetate (6.0 g, 1.0 eq.) were added to 75 ml of dichloroethane, and the temperature was raised to 85°C. Scandium trifluoromethanesulfonate (0.38 g, 0.05 eq.) was added in batches at 85°C, and the mixture was stirred at 85°C for 3 hours, and 16 ml of triethylamine was added to quench the mixture. After the reaction was completed, the reaction system was cooled to 25°C, 60 ml of water and 60 ml of dichloromethane were added to the reaction solution, and the mixture was filtered to separate the organic phase. The organic phase was dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water = 72 / 28, v / v) to obtain an oily compound NM043 (4.5 g). ESI-MS (m / z) = 505.3 [M+H] + .

[0328] Preparation Example 5: Synthesis of Compound NM015

[0329] In this preparation example, the synthesis process of compound NM015 is as follows:

[0330]

[0331] Compound NM015-1 (5 g, 1.1 eq.) and D-galactosamine pentaacetate (8.07 g, 1.0 eq.) were added to 96 ml of dichloroethane, and the temperature was raised to 85°C. Scandium trifluoromethanesulfonate (0.38 g, 0.77 mmol) was added in batches at 85°C, and stirred at 85°C for 3 hours. 16 ml of triethylamine was added to quench. After the reaction was completed, the reaction system was cooled to 25°C, 100 ml of water and 100 ml of dichloromethane were added to the reaction solution, filtered, and the organic phase was separated. The organic phase was dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water = 72 / 28, v / v) to obtain oily compound NM015 (6.6 g). ESI-MS (m / z) = 549 [M+H] + .

[0332] Preparation Example 6: Synthesis of Compound NM064

[0333] In this preparation example, the synthesis process of compound NM064 is as follows:

[0334]

[0335] (6-1) Synthesis of Compound NM064-2

[0336] Compound NM064-1 (13 g, 1.0 eq) was dissolved in 150 ml of acetonitrile, and benzaldehyde dimethyl acetal (30 ml, 3.0 eq) and DL-10-camphorsulfonic acid (1.5 g, 0.1 eq) were added respectively, stirred at 25°C for 5 hours, 3 ml of triethylamine was added, and stirred at 25°C for 30 min. After the reaction was completed, the reaction solution was concentrated, 100 ml of water was added, and extracted with ethyl acetate twice (100 ml×2), the organic phases were combined, dried with anhydrous sodium sulfate, filtered, concentrated, and purified by normal phase purification column (eluent: ethyl acetate / petroleum ether=57 / 43, v / v) to obtain compound NM064-2 (11.5 g, yield 60.8%) as a white solid. MS ESI (m / z)=283[M+H] + .

[0337] (6-2) Synthesis of Compound NM064-3

[0338] Compound NM064-2 (5 g, 1.0 eq) was dissolved in 40 ml of DMF, sodium hydride (2.7 g, 4 eq) was added under ice bath, reacted under ice bath for 30 minutes, 3-bromopropyne (8.1 g, 4 eq) was added, stirred at 25°C for 2 hours, and quenched with 20 ml of water. After the reaction, the reaction solution was extracted 3 times with 50 ml of ethyl acetate (50 ml×3), the organic phases were combined, the organic phases were washed 5 times with 20 ml of saturated sodium chloride solution (20 ml×5), the organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain brown oily NM064-3 (6.3 g, yield 100%). MS ESI (m / z) = 359 [M+H] + .

[0339] (6-3) Synthesis of Compound NM064-4

[0340] Compound NM064-3 (6.3 g, 1.0 eq) was dissolved in 30 ml of DCM, and 300 ml of 70 mass % acetic acid aqueous solution was added, and the mixture was reacted at 70°C for 1 hour. After the reaction was completed, the reaction solution was directly concentrated to obtain a yellow oil compound NM064-4 (4.78 g, yield 100%). MS ESI (m / z) = 271 [M+H] + .

[0341] (6-4) Synthesis of Compound NM064-5

[0342] Compound NM064-4 (4.78 g, 1.0 eq) was dissolved in 50 ml of pyridine, DMTrCl (7.8 g, 1.3 eq) was added under ice bath, nitrogen was replaced 3 times, stirred at 25°C for 3 hours, and quenched with 50 ml of methanol. After the reaction was completed, the reaction solution was concentrated, 50 ml of water was added, and extracted 3 times with 50 ml of ethyl acetate (50 ml×3), the organic phases were combined, dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (eluent: ethyl acetate / petroleum ether=16 / 84, v / v) to obtain compound NM064-5 (6.7 g, yield 66.3%) as a light yellow solid. MS ESI (m / z)=573[M+H] + .

[0343] (6-5) Synthesis of Compound NM064

[0344] Compound NM064-5 (2.0 g, 1.0 eq) was dissolved in 20 ml of anhydrous dichloromethane, and DCI (330.4 mg, 0.8 eq) and bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.16 g, 1.1 eq) were added respectively, and the atmosphere was replaced with nitrogen three times, and stirred at 25°C for 2 hours. After the reaction was completed, 20 ml of saturated sodium bicarbonate aqueous solution was added to the reaction solution, and the mixture was extracted three times with 20 ml of dichloromethane (20 ml×3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water=72 / 28, v / v), and vacuum dried for 12 hours to obtain compound NM064 (2 g, yield 74.07%) as a white powder. MS ESI (m / z)=774[M+H] + .

[0345] 1 H NMR (400MHz, DMSO-d6) δ7.45–7.39(d,J=7.8Hz,2H),7.36–7.18(tt,J=14.5,8.5Hz,7H),6.95–6.84(d ,J=7.5Hz,4H),5.01–4.96(s,1H),4.43–4.28(s,4H),3.81–3.70(s,8H),3.65–3.35(m,12H),3.28–3. 18 (dt, J = 14.5, 7.2 Hz, 1H), 3.06–2.97 (t, J = 9.5 Hz, 1H), 2.75–2.68 (m, 1H), 1.07–0.95 (q, J = 7.4, 6.8 Hz, 10H), 0.84–0.78 (d, J = 6.6 Hz, 2H). Preparation Example 7: Synthesis of Compound CR01022 and Compound CR01022Z (a cluster of CR01022, denoted as (CR01022) × 1)

[0346] In this preparation example, the synthesis process of compound CR01022 and compound CR01022Z is ​​as follows:

[0347]

[0348] (7-1) Synthesis of Compound CR01022-1

[0349] Compound NM015 (1114 mg, 2.03 mmol, 2.2 eq.), compound NM041-7 (500 mg, 0.922 mmol, 1.0 eq.), cuprous iodide (701 mg, 3.69 mmol, 4.0 eq.), N,N-diisopropylethylamine (476 mg, 3.69 mmol, 4.0 eq.) were added to 3 ml of N,N-dimethylformamide solution and stirred at 25°C for 1.5 hours. After the reaction was completed, 5 ml of ethyl acetate and 5 ml of water were added to the reaction solution, filtered, and the organic phase was separated. The organic phase was dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water = 72 / 28, v / v) to obtain foamy compound CR01022-1 (1 g). ESI-MS (m / z) = 1639 [M+H] + .

[0350] (7-2) Synthesis of Compound CR01022

[0351] Compound CR01022-1 (850 mg, 0.523 mmol, 1.0 eq.) was added to 17 ml of dichloromethane, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (313 mg, 1.04 mmol, 2.0 eq.) was added in batches, and then 4,5-dicyanoimidazole (49 mg, 0.415 mmol, 0.8 eq.) was added, and nitrogen was replaced 3 times, and stirred at 25°C for 1 hour. After the reaction was completed, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution for washing once, and the organic phase was separated, concentrated, and purified by column chromatography (C18 column, acetonitrile / water=72 / 28, v / v) to obtain compound CR01022 (560 mg). MS ESI (m / z)=1839[M+H] + .

[0352] (7-3) Synthesis of Compound CR01022Z

[0353] Compound CR01022-1 (160 mg, 0.1 mmol, 1.0 eq.) was added to 3.2 ml of dichloromethane, succinic anhydride (18 mg, 0.18 mmol, 1.8 eq.), 4-dimethylaminopyridine (1.2 mg, 0.01 mmol, 0.01 eq.) and triethylamine (19.7 mg, 0.2 mmol, 2.0 eq.) were added to a 25 ml reaction kettle, and nitrogen was replaced three times, and stirred at 25° C. for 16 hours. After the reaction was completed, column chromatography reverse phase purification (C18 column, acetonitrile / water = 72 / 28, v / v) was performed to obtain 100 mg of the product.

[0354] The above product (100 mg, 0.058 mmol, 1.0 eq.), amino CPG (1.44 g, 0.115 mmol, 80 umol / g), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (32.67 mg, 0.086 mmol, 1.5 eq.) and N,N-diisopropylethylamine (14.8 mg, 0.115 mmol, 2.0 eq.) were mixed, shaken for 16 hours, the reaction solution was filtered, the solid was washed once with 10 ml of acetonitrile and vacuum dried. The solid was mixed with 4-dimethylaminopyridine (2 mg, 0.017 mmol), Cap1 (15 ml) and Cap2 (1.5 ml), shaken for 6 hours, the reaction solution was filtered, the filter cake was washed once with 10 ml of acetonitrile and vacuum dried to obtain compound CR01022Z (1.366 g, loading 20-30 umol / g).

[0355] Wherein, Cap1 and Cap2 are capping reagent solutions, Cap1 is a 20 volume % N-methylimidazole mixed solution in pyridine / acetonitrile, and the volume ratio of pyridine to acetonitrile is 3:5; Cap2 is a 20 volume % acetic anhydride acetonitrile solution.

[0356] Preparation Example 8: Synthesis of Compound CR01027 and Compound CR01027Z (a cluster of CR01027, denoted as (CR01027)×1)

[0357] In this preparation example, the synthesis process of compound CR01027 and compound CR01027Z is as follows:

[0358]

[0359] (8-1) Synthesis of Compound CR01027-1

[0360] Compound NM015 (1125 mg, 2.03 mmol, 2.2 eq.), compound NM064-5 (500 mg, 0.922 mmol, 1.0 eq.), cuprous iodide (701 mg, 3.69 mmol, 4.0 eq.), N,N-diisopropylethylamine (476 mg, 3.69 mmol, 4.0 eq.) were added to 3 ml of N,N-dimethylformamide and stirred at 25°C for 1.5 hours. After the reaction was completed, 5 ml of ethyl acetate and 5 ml of water were added to the reaction solution, filtered, and the organic phase was separated. The organic phase was dried over anhydrous sodium sulfate and concentrated, and purified by column chromatography (C18 column, acetonitrile / water = 72 / 28, v / v) to obtain a foamy compound CR01027-1 (1 g, yield 68.5%). ESI-MS (m / z): 1669.7 [M+H] + .

[0361] (8-2) Synthesis of Compound CR01027

[0362] Compound CR01027-1 (870 mg, 0.530 mmol, 1.0 eq.) was added to 20 ml of dichloromethane, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (330 mg, 1.04 mmol, 2.0 eq.) was added in batches, and then 4,5-dicyanoimidazole (52 mg, 0.415 mmol, 0.8 eq.) was added, and nitrogen was replaced 3 times, and stirred at 25°C for 1 hour. After the reaction was completed, the reaction solution was washed once with sodium bicarbonate aqueous solution, and the organic phase was separated, concentrated, and purified by column chromatography (C18 column, acetonitrile / water=72 / 28, v / v) to obtain compound CR01027 (560 mg, yield 60.8%). MS ESI (m / z) = 1869.8 [M+H] + .

[0363] (8-3) Synthesis of Compound CR01027Z

[0364] Compound CR01027Z was prepared according to the synthesis method of compound CR01022Z (7-3) in Preparation Example 7. Preparation Example 9: Synthesis of Compound CR01020 and Compound CR01020Z

[0365] In this preparation example, the synthesis process of compound CR01020 and compound CR01020Z is as follows:

[0366]

[0367] (9-1) Synthesis of Compound CR01020-1

[0368] Compound NM015 (2.55 g, 4.64 mmol, 2.2 eq.), compound NM014-5 (1.0 g, 2.11 mmol, 1.0 eq.), cuprous iodide (1.61 g, 8.44 mmol, 4.0 eq.), N,N-diisopropylethylamine (1.09 g, 8.44 mmol, 4.0 eq.) were added to 10 ml of N,N-dimethylformamide and stirred at 25°C for 1.5 hours. After the reaction was completed, 15 ml of ethyl acetate and 15 ml of water were added to the reaction solution, filtered, and the organic phase was separated. The organic phase was dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, acetonitrile / water = 72 / 28, v / v) to obtain a foamy compound CR01020-1 (1.6 g, yield 74.1%). ESI-MS (m / z) = 1023.2 [M+H] + .

[0369] (9-2) Synthesis of Compound CR01020

[0370] Compound CR01020-1 (1.0 g, 0.98 mmol, 1.0 eq.) was added to 20 ml of dichloromethane, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (0.59 g, 1.96 mmol, 2.0 eq.) was added in batches, and then 4,5-dicyanoimidazole (92 mg, 0.78 mmol, 0.8 eq.) was added, and nitrogen was replaced 3 times, and stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was washed once with sodium bicarbonate aqueous solution, and the organic phase was separated, dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, acetonitrile / water=72 / 28, v / v) to obtain compound CR01020 (780 mg, yield 65.0%). MS ESI (m / z) = 1223.5 [M+H] + .

[0371] (9-3) Synthesis of Compound CR01020Z

[0372] Compound CR01020Z was prepared according to the synthesis method of compound CR01022Z (7-3) in Preparation Example 7. Preparation Example 10: Synthesis of compound CR01021 and compound CR01021Z (a cluster of CR01021, denoted as (CR01021)×1)

[0373] In this preparation example, the synthesis process of compound CR01021 and compound CR01021Z is as follows:

[0374]

[0375] (10-1) Synthesis of Compound CR01021-1

[0376] Compound NM015 (2.55 g, 4.64 mmol, 2.2 eq.), compound NM014-5A (1.0 g, 2.11 mmol, 1.0 eq.), cuprous iodide (1.61 g, 8.44 mmol, 4.0 eq.), N,N-diisopropylethylamine (1.09 g, 8.44 mmol, 4.0 eq.) were added to 10 ml of N,N-dimethylformamide and stirred at 25°C for 1.5 hours. After the reaction was completed, 15 ml of ethyl acetate and 15 ml of water were added to the reaction solution, filtered, and the organic phase was separated. The organic phase was dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, acetonitrile / water = 72 / 28, v / v) to obtain foamy compound CR01021-1 (1.7 g, yield 78.7%). ESI-MS (m / z): 1023.2 [M+H] + .

[0377] (10-2) Synthesis of Compound CR01021

[0378] Compound CR01020-1 (1.0 g, 0.98 mmol, 1.0 eq.) was added to 20 ml of dichloromethane, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (0.59 g, 1.96 mmol, 2.0 eq.) was added in batches, and then 4,5-dicyanoimidazole (92 mg, 0.78 mmol, 0.8 eq.) was added, and nitrogen was replaced 3 times, and stirred at 25°C for 1 hour. After the reaction was completed, the reaction solution was washed once with sodium bicarbonate aqueous solution, and the organic phase was separated, concentrated, and purified by column chromatography (C18 column, acetonitrile / water=72 / 28) to obtain compound CR01021 (880 mg, yield 73.3%). MS ESI (m / z) = 1223.5 [M+H] + .

[0379] (10-3) Synthesis of Compound CR01021Z

[0380] Compound CR01021Z was prepared according to the synthesis method of compound CR01022Z (7-3) in Preparation Example 7. Preparation Example 11: Synthesis of compound CR01023 and compound CR01023Z (a cluster of CR01023, denoted as (CR01023)×1)

[0381] In this preparation example, the synthesis process of compound CR01023 and compound CR01023Z is as follows:

[0382]

[0383] (11-1) Synthesis of Compound CR01023-1

[0384] Compound NM015 (2.79 g, 5.08 mmol, 2.2 eq.), compound NM042-4 (1.0 g, 2.31 mmol, 1.0 eq.), cuprous iodide (1.76 g, 9.24 mmol, 4.0 eq.), N,N-diisopropylethylamine (1.19 g, 9.24 mmol, 4.0 eq.) were added to 10 ml of N,N-dimethylformamide, stirred at 25°C for 1.5 hours, 15 ml of ethyl acetate and 15 ml of water were added, filtered, separated, the organic phase was dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, acetonitrile / water = 72 / 28, v / v) to obtain foamy compound CR01023-1 (1.6 g, yield 70.5%). ESI-MS (m / z) = 980.2 [M+H] + .

[0385] (11-2) Synthesis of Compound CR01023

[0386] Compound CR01023-1 (1.0 g, 1.02 mmol, 1.0 eq.) was added to 20 ml of dichloromethane, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (0.61 g, 2.04 mmol, 2.0 eq.) was added in batches, and then 4,5-dicyanoimidazole (96 mg, 0.82 mmol, 0.8 eq.) was added, and nitrogen was replaced 3 times, and stirred at 25°C for 1 hour. After the reaction was completed, sodium bicarbonate aqueous solution was added to the reaction solution for washing once, and the organic phase was separated, concentrated, and purified by column chromatography (C18 column, acetonitrile / water=72 / 28, v / v) to obtain compound CR01023 (880 mg, yield 73.3%). MS ESI (m / z) = 1181.5 [M+H] + .

[0387] (11-3) Synthesis of Compound CR01023Z

[0388] Compound CR01023Z was prepared according to the synthesis method of compound CR01022Z (7-3) in Preparation Example 7. Preparation Example 12: Synthesis of compound CR01024 and compound CR01024Z (a cluster of CR01024, denoted as (CR01024)×1)

[0389] In this preparation example, the synthesis process of compound CR01024 and compound CR01024Z is as follows:

[0390]

[0391] (12-1) Synthesis of Compound CR01024-1

[0392] Compound NM043 (2.34 g, 4.64 mmol, 2.2 eq.), compound NM014-5 (1.0 g, 2.11 mmol, 1.0 eq.), cuprous iodide (1.61 g, 8.44 mmol, 4.0 eq.), N,N-diisopropylethylamine (1.09 g, 8.44 mmol, 4.0 eq.) were added to 10 ml of N,N-dimethylformamide and stirred at 25°C for 1.5 hours. After the reaction was completed, 15 ml of ethyl acetate and 15 ml of water were added to the reaction solution, filtered, and the organic phase was separated. The organic phase was dried by adding anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water = 72 / 28, v / v) to obtain foamy compound CR01024-1 (1.7 g, yield 80%). ESI-MS (m / z): 979.2 [M+H] + .

[0393] (12-2) Synthesis of Compound CR01024

[0394] Compound CR01024-1 (1.0 g, 1.02 mmol, 1.0 eq.) and dichloromethane (20 ml) were added to a 25 ml reaction kettle, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (0.61 g, 2.04 mmol, 2.0 eq.) and 4,5-dicyanoimidazole (96 mg, 0.82 mmol, 0.8 eq.) were added in batches, and nitrogen was replaced 3 times. The mixture was stirred at room temperature for 1 hour, and sodium bicarbonate aqueous solution was added to wash once, and the mixture was separated. The organic phase was concentrated and purified by column chromatography (C18 column, acetonitrile / water=72 / 28, v / v) to obtain compound CR01024 (770 mg, yield 64.2%). MS ESI (m / z)=1179.5[M+H] + .

[0395] (12-3) Synthesis of Compound CR01024Z

[0396] Compound CR01024Z was prepared according to the synthesis method of compound CR01022Z (7-3) in Preparation Example 7. Preparation Example 13: Synthesis of compound CR01025 and compound CR01025Z (a cluster of CR01025, denoted as (CR01025)×1)

[0397] In this preparation example, the synthesis process of compound CR01025 and compound CR01025Z is as follows:

[0398]

[0399] (13-1) Synthesis of Compound CR01025-1

[0400] Compound NM043 (2.34 g, 4.64 mmol, 2.2 eq.), compound NM14-5A (1.0 g, 2.11 mmol, 1.0 eq.), cuprous iodide (1.61 g, 8.44 mmol, 4.0 eq.), N,N-diisopropylethylamine (1.09 g, 8.44 mmol, 4.0 eq.) were added to 10 ml of N,N-dimethylformamide and stirred at 25°C for 1.5 hours. After the reaction was completed, 15 ml of ethyl acetate and 15 ml of water were added to the reaction solution, filtered, and the organic phase was separated. The organic phase was dried by adding anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, acetonitrile / water = 72 / 28, v / v) to obtain foamy compound CR01025-1 (1.7 g, yield 80%). ESI-MS (m / z) = 979.2 [M+H] + .

[0401] (13-2) Synthesis of Compound CR01025

[0402] Compound CR01025-1 (1.0 g, 1.02 mmol, 1.0 eq.) was added to 20 ml of dichloromethane, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (0.61 g, 2.04 mmol, 2.0 eq.) was added in batches, and then 4,5-dicyanoimidazole (96 mg, 0.82 mmol, 0.8 eq.) was added, and nitrogen was replaced 3 times, and stirred at room temperature for 1 hour. After the reaction was completed, sodium bicarbonate aqueous solution was added to the reaction solution for washing once, and the organic phase was separated, concentrated, and purified by column chromatography (C18 column, acetonitrile / water=72 / 28, v / v) to obtain compound CR01025 (775 mg, yield 64.3%). MS ESI (m / z) = 1179.5 [M+H] + .

[0403] (13-3) Synthesis of Compound CR01025Z

[0404] Compound CR01025Z was prepared according to the synthesis method of compound CR01022Z (7-3) in Preparation Example 7. Preparation Example 14: Synthesis of compound CR01026 and compound CR01026Z (a cluster of CR01026, denoted as (CR01026)×1)

[0405] In this preparation example, the synthesis process of compound CR01026 and compound CR01026Z is as follows:

[0406]

[0407] (14-1) Synthesis of Compound CR01026-1

[0408] Compound NM043 (4.08 g, 8.10 mmol, 4.4 eq.), compound NM041-7 (1.0 g, 1.84 mmol, 1.0 eq.), cuprous iodide (2.10 g, 11.04 mmol, 6.0 eq.), N,N-diisopropylethylamine (1.43 g, 11.04 mmol, 6.0 eq.) were added to 20 ml of N,N-dimethylformamide and stirred at 25°C for 1.5 hours. After the reaction was completed, 25 ml of ethyl acetate and 25 ml of water were added to the reaction solution, filtered, and the organic phase was separated. The organic phase was dried by adding anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, acetonitrile / water = 72 / 28, v / v) to obtain foamy compound CR01026-1 (2.5 g, yield 87.4%). ESI-MS (m / z) = 1551.2 [M+H] + .

[0409] (14-2) Synthesis of Compound CR01026

[0410] Compound CR01026-1 (1.0 g, 0.64 mmol, 1.0 eq.) was added to 20 ml of dichloromethane, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (0.39 g, 1.28 mmol, 2.0 eq.) was added in batches, and then 4,5-dicyanoimidazole (60 mg, 0.51 mmol, 0.8 eq.) was added, and nitrogen was replaced 3 times, and stirred at 25°C for 1 hour. After the reaction was completed, sodium bicarbonate aqueous solution was added to the reaction solution for washing once, and the organic phase was separated, concentrated, and purified by column chromatography (C18 column, acetonitrile / water=72 / 28, v / v) to obtain compound CR01026 (670 mg, yield 55.8%). MS ESI (m / z) = 1751.5 [M+H] + .

[0411] (14-3) Synthesis of Compound CR01026Z

[0412] Compound CR01026Z was prepared according to the synthesis method of compound CR01022Z (7-3) in Preparation Example 7. Preparation Example 15: Synthesis of compound CR01017 and compound CR01017Z (a cluster of CR01017, denoted as (CR01017)×1)

[0413] In this preparation example, the synthesis process of compound CR01017 and compound CR01017Z is as follows:

[0414]

[0415] (15-1) Synthesis of Compound CR01017-1

[0416] Compound NM041-4 (4.3 g, 17.0 mmol, 1.0 eq) was dissolved in 50 ml of ultra-dry DMF, and NaH (2.7 g, 68 mmol, 4.0 eq) was added under ice bath and stirred for 1 hour; ethyl bromoacetate (5.7 g, 34 mmol, 2.0 eq, CAS No. 105-36-2) and KI (4.3 g, 25.9 mmol, 1.5 eq) were added and reacted at 25°C for 3 hours, and saturated aqueous ammonium chloride solution was added to quench. After the reaction was completed, 20 ml of water was added to the reaction solution, and the mixture was extracted 3 times with 50 ml of ethyl acetate (50 ml×3), the organic phases were combined, and the organic phases were washed 10 times with 20 ml of saturated aqueous sodium chloride solution (20 ml×10), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound CR01017-1 as a dark brown oil, which was directly used in the next step. MS ESI (m / z) = 425.2 [M+H] + .

[0417] (15-2) Synthesis of Compound CR01017-2

[0418] CR01017-1 (5 g, 1.0 eq) was dissolved in 30 ml of dichloromethane (DCM), and 300 ml of 70 mass % glacial acetic acid aqueous solution was added, and stirred at 50°C for 2 hours. After the reaction was completed, the reaction solution was directly concentrated to obtain a dark brown oily compound CR01017-2, which was directly used in the next step. MS ESI (m / z) = 337 [M+H] + .

[0419] (15-3) Synthesis of Compound CR01017-3

[0420] Compound CR01017-2 (3.2 g, 9.52 mmol, 1.0 eq) was dissolved in 70 ml of pyridine, DMTrCl (4.19 g, 12.4 mmol, 1.3 eq) was added under ice bath, stirred at 25°C for 3 hours, and quenched by adding 30 ml of methanol. After the reaction was completed, the reaction solution was concentrated, 20 ml of water was added, and extracted with 50 ml of ethyl acetate 3 times (50 ml×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water=52 / 48, v / v) to obtain compound CR01017-3 (5 g, yield 83%) as a yellow solid. MS ESI (m / z)=639[M+H] + .

[0421] (15-4) Synthesis of Compound CR01017-4

[0422] Compound CR01017-3 (2 g, 3.16 mmol, 1.0 eq) was dissolved in 10 ml of methanol, and an aqueous solution of NaOH (6.3 ml, 1 mol / L) was added, and stirred at 25°C for 1 hour. After the reaction was completed, the pH of the reaction solution was adjusted to neutral with hydrochloric acid, the reaction solution was filtered, the filtrate was concentrated, and column chromatography reverse phase purification (C18 column, eluent: acetonitrile / water = 26 / 74, v / v) was performed to obtain compound CR01017-4 (920 mg, yield 51%) as a light yellow solid. MS ESI (m / z) = 583 [M+H] + .

[0423] (15-5) Synthesis of Compound CR01017-5

[0424] Compound CR01017-4 (900 mg, 1.55 mmol, 1 eq), (2R, 3R, 4R, 5R, 6R)-5-acetylamino-2-(acetoxymethyl)-6-(2-(2-(aminoethoxy)ethoxy) (2.02 g, 3.88 mmol, 2.5 eq) and HATU (1.35 g, 3.56 mmol, 2.3 eq) were dissolved in 25 ml of N,N-dimethylformamide, DIEA (800 mg, 6.2 mmol, 4.0 eq) was added under ice bath, and stirred at 25°C for 12 hours. After the reaction, column chromatography reverse phase purification (C18 column, eluent: acetonitrile / water = 20 / 80, v / v) was performed to obtain compound CR01017-5 (700 mg, yield 28.6%) as a white solid. MS ESI (m / z) = 1591.2 [M+H] + .

[0425] (15-6) Synthesis of Compound CR01017

[0426] Compound CR01017-5 (500 mg, 0.31 mmol, 1.0 eq), 4,5-dicyanoimidazole (30 mg, 0.25 mmol, 0.8 eq) and bis(diisopropylamino)(2-cyanoethoxy)phosphine (138 mg, 0.46 mmol, 1.5 eq) were dissolved in 10 ml of ultra-dry dichloromethane and reacted at 25° C. for 2 hours in a nitrogen atmosphere. After the reaction was completed, the reaction solution was washed twice with 10 ml of saturated sodium bicarbonate (10 ml×2), the organic phase was concentrated, and column chromatography was performed for reverse phase purification (C18 column, eluent: acetonitrile / water=80 / 20, v / v) to obtain compound CR01017 (480 mg, yield 83.1%) as a white solid. MS ESI (m / z)=1791.2[M+H] + .

[0427] (15-7) Synthesis of Compound CR01017-6

[0428] Compound CR01017-5 (200 mg, 0.13 mmol, 1.0 eq) was dissolved in 10 ml of dichloromethane, succinic anhydride (14 mg, 0.14 mmol, 1.1 eq) and triethylamine (26 mg, 0.26 mmol, 2.0 eq) were added, and stirred at 25°C for 12 hours. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography (C18 column, eluent: acetonitrile / water = 36 / 64, v / v) to obtain compound CR01017-6 (150 mg, yield 71.4%) as a white solid. MS ESI (m / z) = 1691.2 [M+H] + .

[0429] (15-8) Synthesis of Compound CR01017Z

[0430] Compound CR01017-6 (70 mg, 0.041 mmol, 1.0 eq), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (22 mg, 0.062 mmol, 1.5 eq, abbreviated as HBTU), and N,N-diisopropylethylamine (10 mg, 0.082 mmol, 2.0 eq) were dissolved in 10 ml of acetonitrile, stirred at 25°C for 5 minutes, aminoCPG (970 mg, 80 umol / g) was added, and the mixture was reacted on a shaking table at 25°C for 18 hours. The mixture was filtered, and the filter cake was washed twice with 10 ml of dichloromethane (10 ml×2) and then washed twice with 10 ml of acetonitrile (10 ml×2). The filter cake, DMAP (3 mg, 0.024 mmol), Cap1 (10 ml) and Cap2 (1 ml) were mixed, reacted on a shaking table at 25°C for 5 hours, filtered, and the filter cake was rinsed three times with 10 ml of acetonitrile and dried to obtain compound CR01017Z (720 mg).

[0431] Wherein, Cap1 and Cap2 are capping reagent solutions, Cap1 is a 20 volume % N-methylimidazole mixed solution in pyridine / acetonitrile, and the volume ratio of pyridine to acetonitrile is 3:5; Cap2 is a 20 volume % acetic anhydride acetonitrile solution.

[0432] Preparation Example 16: Synthesis Method 1 of siRNA Conjugate

[0433] (16-1) Synthesis of positive chain SS

[0434] By the phosphoramidite nucleic acid solid phase synthesis method, starting with the above-mentioned compounds connected to the solid phase carrier (i.e., CR01017Z, CR01020Z, CR01021Z, CR01022Z, CR01023Z, CR01024Z, CR01025Z, CR01026Z, CR01027Z, L96-PS), the nucleoside monomers are connected one by one in a 3'-5' direction according to the nucleotide sequence (the compounds CR01017, CR01020, CR01021, CR01022, CR01023, CR01024, CR01025 and CR01026 can be regarded as a nucleoside monomer respectively).

[0435] Each connection of a nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization. The synthesis conditions are given as follows:

[0436] The nucleoside monomer was prepared into an acetonitrile solution with a concentration of 0.1 M.

[0437] The conditions of the deprotection reaction in each step are the same. The conditions of the deprotection reaction are: temperature of 25° C., reaction time of 70 seconds, deprotection reagent of dichloroacetic acid in dichloromethane solution (3% by volume), and the molar ratio of dichloroacetic acid to 4,4'-dimethoxytrityl protecting group on the solid phase carrier is 5:1.

[0438] The conditions of each coupling reaction are the same. The coupling reaction conditions are: temperature is 25°C, the molar ratio of the nucleic acid sequence connected to the solid phase support to the nucleoside monomer is 1:10, the molar ratio of the nucleic acid sequence connected to the solid phase support to the coupling reagent is 1:65, the reaction time is 600 seconds, the coupling reagent is an acetonitrile solution of 5-ethylthio-1H-tetrazole with a concentration of 0.5M, and the thiolation reagent is an acetonitrile / pyridine mixed solution of hydrogenated xanthanol with a concentration of 0.2M (the volume ratio of acetonitrile and pyridine is 1:1).

[0439] The conditions of each capping reaction are the same. The conditions of the capping reaction are: temperature is 25°C; reaction time is 2 minutes; the capping reagent solution is a mixed solution of Cap1 and Cap2 with a molar ratio of 1:1, Cap1 is a pyridine / acetonitrile mixed solution of N-methylimidazole with a concentration of 20 volume%, the volume ratio of pyridine to acetonitrile is 3:5, Cap2 is an acetonitrile solution of acetic anhydride with a volume ratio of 20 volume%; the molar ratio of N-methylimidazole in Cap1 capping reagent, acetic anhydride in Cap2 capping reagent to the nucleic acid sequence connected to the solid phase carrier is 1:1:1.

[0440] The conditions for each step of the oxidation reaction are the same. The conditions for the oxidation reaction are: temperature of 25°C; reaction time of 3 seconds; oxidation reagent concentration of 0.05M iodine water, the molar ratio of iodine to the nucleic acid sequence connected to the solid phase carrier in the coupling reaction is 30:1; oxidation reaction is carried out in a water / pyridine mixed solvent (the volume ratio of water to pyridine is 1:9). The conditions for the sulfidation reaction are: temperature of 25°C; reaction time of 360 seconds; thiolation reagent concentration of 0.2M hydrogenated xanthan gum pyridine solution, the molar ratio of thiolation reagent to the nucleic acid sequence connected to the solid phase carrier in the coupling reaction is 4:1; thiolation reaction is carried out in a water / pyridine mixed solvent (the volume ratio of water to pyridine is 1:9).

[0441] After the last nucleoside monomer is connected, the nucleic acid sequence connected to the solid phase carrier is cut, deprotected, purified, desalted, and then freeze-dried to obtain the positive chain, wherein:

[0442] The cleavage and deprotection conditions are as follows: the synthesized nucleotide sequence connected to the solid phase carrier is added to 25% by mass ammonia water, the amount of ammonia water is 0.5 ml / μmol, the reaction is carried out at 55°C for 16 hours, the solvent is removed, and the product is concentrated to dryness in vacuo. After the ammonia water treatment, the product is dissolved with 0.4 ml / μmol N-methylpyrrolidone relative to the amount of single-stranded nucleic acid, and then 0.3 ml / μmol triethylamine and 0.6 ml / μmol triethylamine trihydrofluoride are added to remove the 2'-O-TBDMS protection on the ribose.

[0443] Purification and desalting conditions: The nucleic acid was purified by gradient elution of NaCl using a preparative ion chromatography purification column (Source 15Q). Specifically, eluent 1 was 20 mM sodium phosphate (pH = 8.1), and the solvent was a water / acetonitrile mixed solution (the volume ratio of water to acetonitrile was 9:1); eluent 2 was 1.5 M sodium chloride, 20 mM sodium phosphate (pH = 8.1), and the solvent was a water / acetonitrile mixed solution (the volume ratio of water to acetonitrile was 9:1); the eluent was eluent 1: eluent 2 = (100:0)-(50:50). The product eluates were collected and combined, and desalted using a reverse chromatographic purification column. The desalting conditions included desalting using a dextran gel column, the filler was dextran gel G25, and eluted with deionized water.

[0444] Detection: Use ion exchange chromatography (IEX-HPLC) for purity detection; use liquid chromatography-mass spectrometry (LC-MS, Liquid ChromatogRLhy-Mass Spectrometry, purchased from Waters, model: LCT Premier) for molecular weight detection, and compare the measured value of the molecular weight with the theoretical value. If the measured value is consistent with the theoretical value, it indicates that the compound is conjugated to the 3' end of the siRNA sense chain.

[0445] During the synthesis of the sense chain, the following ligands (carriers) were synthesized:

[0446] The structural formula of the two clusters of CR01017 (denoted as (CR01017)×2) is:

[0447]

[0448] The structural formula of three clusters of CR01020 (denoted as (CR01020)×3) is:

[0449]

[0450] The structural formula of three clusters of CR01021 (denoted as (CR01021)×3) is:

[0451]

[0452] The structural formula of the two clusters of CR01022 (denoted as (CR01022)×2) is:

[0453]

[0454] The structural formula of three clusters of CR01022 (denoted as (CR01022)×3) is:

[0455]

[0456] The structural formula of three clusters of CR01023 (denoted as (CR01023)×3) is:

[0457]

[0458] The structural formula of three clusters of CR01024 (denoted as (CR01024)×3) is:

[0459]

[0460] The structural formula of three clusters of CR01025 (denoted as (CR01025)×3) is:

[0461]

[0462] The structural formula of the two clusters of CR01026 (denoted as (CR01026)×2) is:

[0463]

[0464] The structural formula of the two clusters of CR01027 (denoted as (CR01027)×2) is:

[0465]

[0466] (16-2) Synthesis of antisense strand (AS)

[0467] The antisense chain was synthesized using a universal solid phase carrier. The deprotection, coupling, capping, oxidation or sulfurization reaction conditions, cleavage and deprotection conditions, purification and desalting conditions in the solid phase synthesis method of the antisense chain are the same as those in step (16-1) for synthesizing the sense chain.

[0468] Detection: Use ion exchange chromatography (IEX-HPLC) for purity detection; use liquid chromatography-mass spectrometry (LC-MS, Liquid ChromatogRLhy-Mass Spectrometry, purchased from Waters, model: LCT Premier) for molecular weight detection, and compare the measured molecular weight with the theoretical value. If the measured value is consistent with the theoretical value, it indicates that the siRNA antisense chain is obtained.

[0469] (16-3) Synthesis of siRNA conjugates

[0470] The sense chain synthesized in step (16-1) and the antisense chain synthesized in step (16-2) are mixed in an equimolar ratio, dissolved in water for injection and heated to 95°C, slowly cooled to room temperature and kept at room temperature for 10 minutes, so that the sense chain and the antisense chain form a double-stranded structure through hydrogen bonds, thereby obtaining a target siRNA conjugate.

[0471] Detection: Each conjugate was diluted to a concentration of 0.2 mg / ml (based on siRNA) using ultrapure water (Milli-Q ultrapure water instrument, resistivity 18.2 MΩ*cm (25°C)), and then the molecular weight was detected using a liquid chromatography-mass spectrometer (LC-MS, Liquid ChromatogRLhy-MassSpectrometry, purchased from Waters, model: LCT Premier). The measured value was consistent with the theoretical value, indicating that the synthesized conjugate was the double-stranded nucleic acid sequence of the target design.

[0472] Preparation Example 17: Synthesis Method 2 of siRNA Conjugate

[0473] In this preparation example, in the siRNA conjugate provided by the present disclosure, the linking group used to connect the siRNA and the ligand group is shown in Formula A (NM014, NM014A, NM041 and NM042):

[0474]

[0475] The ligand group is shown in Formula B (NM015 and NM043):

[0476]

[0477] Taking the linker group NM041 and the ligand group NM015 as an example, the siRNA synthesis process includes the following steps: (17-1) Synthesis of the positive strand

[0478] The synthetic route of the positive chain is as follows:

[0479]

[0480] Specifically, the method for preparing the sense strand includes the following steps:

[0481] S1. Compound NM041 is regarded as a nucleoside monomer. Compound NM041 is connected to a solid phase carrier by a phosphoramidite solid phase synthesis method. Then, nucleoside monomers are connected one by one in the direction from 3' to 5' according to the nucleotide type and order of the sense chain of the above siRNA sequence. The connection of each nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization. The deprotection, coupling, capping, oxidation or sulfurization reaction conditions in the synthesis of the sense chain are the same as those in step (16-1) for synthesizing the sense chain.

[0482] The sense strand hemiconjugate containing the linker group (denoted as SS-(NM041)×2) was separated, wherein the linker group NM041 was connected to the 3' end of the sense strand of the siRNA.

[0483] The terminal alkyne group in S2 and SS-(NM041)×2 was conjugated with the ligand group NM015 via a click reaction to obtain a positive chain conjugate.

[0484] S2-1. Mix 150 μL of H2O, 70 μL of 0.2 mol / L carbonate buffer solution (pH = 9.2) and 70 μL of N,N-dimethylformamide (DMF) to obtain a mixed solvent; dissolve SS-(NM041)×2 in the mixed solvent to obtain a SS-(NM041)×2 solution with a concentration of 1.0 eq.

[0485] S2-2. Dissolve 6.0 eq of ligand compound NM015 in 70 μL of DMF to obtain NM015 solution.

[0486] S2-3. Mix the SS-(NM041)×2 solution obtained in step S2-1 and the NM015 solution obtained in step S2-2 to obtain a reactant mixture.

[0487] S2-4. Take 10.0 eq of tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) and 3.0 eq of CuSO4·5H2O and mix them in a volume ratio of THPTA:CuSO4·5H2O=10:3. After shaking at 40°C for 5 min, take 37 μL and add it to the reactant mixture obtained in the above step S2-3, and vortex shake to obtain an intermediate product mixture. The pH of the intermediate product mixture is measured to be 8.

[0488] S3. Take 25.0 eq of sodium ascorbate and quickly add it to the intermediate product mixture obtained in step 2-4, and vortex it for treatment. React it at 40° C. for 1 h to obtain a product mixture.

[0489] S4, purification: Take 3 μL of the product mixture obtained in step S3, dilute the product mixture with a mixed solution of DMF and H2O (the volume ratio of DMF and H2O is 1:5), and then separate and purify it by HPLC. The chromatographic column used in the HPLC treatment process is a C18 chromatographic column, the mobile phase is an ammonium bicarbonate buffer solution, and a gradient elution method is adopted. The product after HPLC treatment and purification is freeze-dried.

[0490] (17-2) Synthesis of antisense strand

[0491] Prepared according to the synthesis method of the antisense chain (AS) in Preparation Example 16 (16-2).

[0492] (17-3) Synthesis of siRNA conjugates

[0493] Prepared according to the synthesis method of siRNA conjugate (16-3) in Preparation Example 16.

[0494] In the two methods for synthesizing siRNA conjugates provided in the present disclosure, the first method for synthesizing the siRNA conjugate is to first synthesize the carrier, then synthesize the sense chain conjugate, and finally synthesize the siRNA conjugate; the second method for synthesizing the siRNA conjugate is to first synthesize the sense chain half conjugate, then synthesize the sense chain conjugate, and finally synthesize the siRNA conjugate.

[0495] Among them, when synthesizing the same amount of siRNA conjugates, compared with synthesis method 2, synthesis method 1 uses less raw materials in synthesizing the carrier, but takes longer to synthesize the siRNA conjugate; compared with synthesis method 1, synthesis method 2 takes less time to synthesize the siRNA conjugate, but uses more raw materials in synthesizing the carrier.

[0496] When the vector is a cluster of CR01017, the structural formula of the siRNA conjugate is as follows:

[0497]

[0498] When the vector is two clusters of CR01017, the structural formula of the siRNA conjugate is as follows:

[0499]

[0500] When the vector is three clusters of CR01020, the structural formula of the siRNA conjugate is as follows:

[0501]

[0502] When the vector is three clusters of CR01021, the structural formula of the siRNA conjugate is as follows:

[0503]

[0504] When the carrier is a cluster of CR01022, the structural formula of the siRNA conjugate is:

[0505]

[0506] When the carrier is two clusters of CR01022, the structural formula of the siRNA conjugate is:

[0507]

[0508] When the vector is three clusters of CR01022, the structural formula of the siRNA conjugate is:

[0509]

[0510] When the vector is three clusters of CR01023, the structural formula of the siRNA conjugate is:

[0511]

[0512] When the vector is three clusters of CR01024, the structural formula of the siRNA conjugate is:

[0513]

[0514] When the vector is three clusters of CR01025, the structural formula of the siRNA conjugate is:

[0515]

[0516] When the carrier is two clusters of CR01026, the structural formula of the siRNA conjugate is:

[0517]

[0518] When the carrier is two clusters of CR01027, the structural formula of the siRNA conjugate is:

[0519]

[0520] When the carrier is L96, the structural formula of the siRNA conjugate is:

[0521]

[0522] The present invention synthesized the siRNA conjugates in Table 3 according to the methods of Preparation Example 16 and Preparation Example 17, respectively.

[0523] In the present disclosure, the conjugates RZ502031, RZ599001, RZ597002, RZ899038, RZ899041, and RZ899042 can only be synthesized using the synthesis method of the siRNA conjugate described in Preparation Example 16.

[0524] Conjugates RZ802008, RZ802009, RZ899007, RZ802014, RZ899022, RZ899023, RZ899024, RZ802010, RZ899009, RZ899011, RZ899040, RZ899025, RZ802011, RZ899010, RZ899048, and RZ897013 can be synthesized using either the synthesis method 1 of the siRNA conjugate described in Preparation Example 16 or the synthesis method 2 of the siRNA conjugate described in Preparation Example 17. Specifically, in the present disclosure, conjugates RZ802010, RZ899009, RZ899011, and RZ899040 were synthesized using the synthesis method 1 of the siRNA conjugate recorded in Preparation Example 16; conjugates RZ802008, RZ802009, RZ899007, RZ802014, RZ899022, RZ899023, RZ899024, RZ899025, RZ802011, RZ899010, RZ899048, and RZ897013 were synthesized using the synthesis method 2 of the siRNA conjugate recorded in Preparation Example 17.

[0525] UmsUmsUmUmAmAmUfCfCfUmCmAmCmUmCmUmAmAmAm, as shown in SEQ ID No.1;

[0526] UmsUfsUmAmGmAfGmUmGmAmGmGmAmUfUmAfAmAmAmsUmsGm, as shown in SEQ ID No. 2;

[0527] CmsAmsGmAmCmAmGfAfCfAmAmGmAmCmCmAmUmCm, as shown in SEQ ID No.3;

[0528] AmsGfsAmUmGmGfUmCmUmUmGmUmCmUfGmUfCmUmGmsGmsAm, as shown in SEQ ID No.4;

[0529] CmsAmsGmAmCmAmGfAfCfAmAmGmAmCmCmAmUmCmUm, as shown in SEQ ID No.5;

[0530] CmsCmsAmAmGmAmGfCfAfCmCmAmAmGmAmAmCmUmAm, as shown in SEQ ID No.6;

[0531] UmsAfsGmUmUmCfUmUmGmGmUmGmCmUfCmUfUmGmGmsUmsUm, as shown in SEQ ID No.7.

[0532] Table 3 siRNA conjugates

[0533]

[0534]

[0535]

[0536] Unless otherwise specified, the base composition and modification meanings described in the embodiments of the present disclosure are as follows: capital letters A, U, G, C, and T represent the base composition of the nucleotides; the lowercase letter m represents that the nucleotide represented by the previous letter is a methoxy-modified nucleotide; the lowercase letter f represents that the nucleotide represented by the previous letter is a fluorinated-modified nucleotide; the lowercase letter s represents that the nucleotides represented by the two letters before and after it are connected by a thiophosphate bond.

[0537] Unless otherwise specified, the siRNA sequences used in this application and this disclosure were commissioned to Suzhou Beixin Biotechnology Co., Ltd. for synthesis; the PCR primers used in this application and this disclosure were commissioned to Beijing Qingke Biotechnology Co., Ltd. for synthesis; the experimental animals C57BL / 6J mice used in this application and this disclosure were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd.

[0538] Table 4 Detection results of siRNA conjugates

[0539]

[0540]

[0541] It can be seen from the data in Table 4 that the sense strand (SS) and the antisense strand (AS) can be well connected to the ligand with a high purity.

[0542] General Experiments

[0543] Method for evaluating target gene inhibitory activity in mice

[0544] 6-8 week old C57BL / 6J mice were randomly divided into groups according to body weight (all female). The mice in each group were given a single dose of drug according to body weight, and the siRNA conjugates were configured with PBS solution to the corresponding concentration (calculated as siRNA) solution for administration, and the administration volume was 5ml / kg (calculated as mouse body weight). The PBS control group was given PBS solution (without drug conjugates), and the administration volume was 5ml / kg (calculated as mouse body weight). The day of administration was recorded as the first day (recorded as D1), and 5 mice were killed in each group at the preset time after administration. The mice killed were grossly dissected and the liver tissue of each killed mouse was collected, and the liver tissue was cut into about 2mm 3 Small pieces were stored with RNA Later.

[0545] Liver tissue samples at different time points in different experimental groups were taken from the above RNA later, and the liver tissue samples were broken in a Tissuelyser II fully automatic tissue homogenizer for 60 seconds, and then total RNA was extracted using a fully automatic nucleic acid extractor (purchased from Zhejiang Hanwei Technology Co., Ltd.) and a nucleic acid extraction kit (purchased from Zhejiang Hanwei Technology Co., Ltd.) according to the standard operating procedures for total RNA extraction.

[0546] Take the above 1 μg total RNA, use the reverse transcription kit (Promega, Reverse Transcription System, A3500) and select Oligo (dT) 15 reverse transcription primer, prepare 20 μL reverse transcription system according to the method described in the reverse transcription kit manual and complete the reverse transcription reaction. After the reaction is completed, add 80 μL RNase-Free water to the reverse transcription system to obtain cDNA solution. Then use the real-time fluorescence quantitative PCR kit (ABI, SYBR TMSelect MasterMix, Catalog number: 4472908) to detect the expression of target gene mRNA in liver tissue. In this real-time fluorescence quantitative PCR method, primers for the target gene and primers for the internal reference gene are used to detect the target gene and the internal reference gene respectively. According to the method described in the instruction manual of the real-time fluorescence quantitative PCR kit, 20μL real-time PCR reaction system is configured for each PCR detection well, and each reaction system contains 5μL of cDNA solution obtained by the above reverse transcription reaction, 10μL SYBR TM Select Master Mix, 0.5 μL 10 μM upstream primer, 0.5 μL 10 μM downstream primer, 4 μL RNase-Free H2O. Place the prepared reaction system in a real-time fluorescence quantitative PCR instrument (ABI, StepOnePlus TM ), a three-step method was used for Real-time PCR amplification, and the amplification program was 95°C pre-denaturation for 10 minutes, followed by 95°C denaturation for 30 seconds, 60°C annealing for 30 seconds, and 72°C extension for 30 seconds, and the denaturation, annealing, and extension process were repeated for 40 cycles. In this real-time fluorescence quantitative PCR method, the ΔΔCt method was used to perform relative quantitative calculations on the expression level and inhibition rate of the target gene mRNA in each test group, and the calculation method was as follows:

[0547] ΔCt(test group) = Ct(test group target gene) – Ct(test group reference gene)

[0548] ΔCt(control group) = Ct(control group target gene) – Ct(control group internal reference gene)

[0549] ΔΔCt(test group) = ΔCt(test group) – ΔCt(average of control group)

[0550] ΔΔCt(control group) = ΔCt(control group) – ΔCt(control group average)

[0551] Among them, ΔCt (control group average) is the arithmetic mean of the ΔCt (control group) of 5 mice sacrificed at the same time point in the control group. Therefore, each mouse in the test group and the control group corresponds to a ΔΔCt value.

[0552] The target gene mRNA expression level of the test group was normalized with the control group as the benchmark, and the target gene mRNA expression level of the control group was defined as 100%.

[0553] Relative expression level of target gene mRNA in the test group = 2-ΔΔCt (test group) × 100%

[0554] Test group target gene mRNA inhibition rate = (1-test group target gene mRNA relative expression level) × 100%

[0556] Unless otherwise stated, the in vivo activity data are based on The experimental data were plotted and analyzed using GraphPad prism 8.0 software.

[0557] Example 1: Evaluation of in vivo activity of three clusters of CR01020 vector-conjugated complement component 3 (CC3) siRNA

[0558] In this example, the in vivo target gene inhibitory activity evaluation method was used to evaluate the inhibitory activity of siRNA conjugates RZ802008 and RZ802009 conjugated with three clusters of CR01020 vectors at the 3' end of the siRNA sense strand at the same CC3 target site, and siRNA conjugate RZ502031 conjugated with L96 vector on the target gene CC3 in mice.

[0559] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, with 15 mice in each group. Each group of mice was given PBS solution and the siRNA conjugate mentioned in this example by subcutaneous administration in the abdomen, wherein the dose given to each mouse in the PBS control group was 5 ml / kg; the dose given to each mouse in the siRNA conjugate experimental group was 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 15th day (D15), and 5 mice were killed in each group on the 29th day (D29). Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0560] The primer sequences of this example are shown in Table 5.

[0561] Table 5 Primer sequence list

[0562]

[0563] The results of Example 1 show that the in vivo activity and duration of the conjugate RZ802008, in which the 3' end of the siRNA sense strand is conjugated with three clusters of CR01020, are substantially equivalent to those of the conjugate RZ502031, in which the 3' end of the siRNA sense strand is conjugated with L96; the three clusters of CR01020 conjugate RZ802009 has better in vivo activity and comparable pharmacodynamic duration than the L96 conjugate RZ502031 ( Figure 1 , Table 6).

[0564] Table 6 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0565]

[0566]

[0567] Example 2: In vivo activity evaluation of three clusters of CR01020 vectors conjugated with superoxide dismutase 1 (SOD1) siRNA

[0568] This example uses the in vivo target gene inhibition activity evaluation method to evaluate the inhibitory activity of the target gene SOD1 in mice by using the siRNA conjugate RZ899007, which is conjugated with three clusters of CR01020 vectors at the 3' end of the siRNA sense strand at the same SOD1 target site, and the conjugate RZ599001, which is conjugated with the L96 vector.

[0569] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 20 mice in each group, 3 groups in total. Each group of mice was administered subcutaneously in the abdomen with PBS solution and the siRNA conjugates mentioned in the present embodiment, wherein the dosage of each mouse in the PBS control group was 5 ml / kg, and the dosage of each mouse in the siRNA conjugate experimental group was 1 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 15th day (D15), 5 mice were killed in each group on the 29th day (D29), and 5 mice were killed in each group on the 43rd day (D43). Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0570] The primer sequences of this example are shown in Table 7.

[0571] Table 7 Primer sequence list

[0572]

[0573] The results of Example 2 show that the conjugate RZ899007, in which the 3' end of the siRNA sense strand is conjugated with three clusters of CR01020, has comparable maximum inhibitory activity and better sustained efficacy than the conjugate RZ599001, in which the 3' end of the siRNA sense strand is conjugated with L96 ( Figure 2 , Table 8).

[0574] Table 8 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0575]

[0576] Example 3: In vivo activity evaluation of three clusters of CR01021 vectors and three clusters of CR01020 vectors conjugated with CC3 target siRNA

[0577] This example uses a method for evaluating the in vivo target gene inhibition activity in mice to evaluate the inhibitory activity of the target gene CC3 in mice by using the siRNA conjugate RZ802014 conjugated with three clusters of CR01021 vectors at the 3' end of the sense strand of the siRNA at the same CC3 target site, the siRNA conjugate RZ802009 conjugated with three clusters of CR01020 vectors, and the conjugate RZ502031 conjugated with the L96 vector. The difference between the three clusters of CR01021 and the three clusters of CR01020 vectors is that the cyclic core parts are isomers of each other.

[0578] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 10 mice in each group, a total of 4 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in this embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and 5 mice were killed in each group on the 8th day (D8) and 5 mice were killed in each group on the 22nd day (D22) after administration. Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0579] The primer sequences of this example are shown in Table 5 in Example 1.

[0580] The results of Example 3 show that the in vivo activity of the three-cluster CR01021 conjugate RZ802014 is superior to that of the L96 conjugate RZ502031; the pharmacodynamic activity of the three-cluster CR01020 conjugate RZ802009) is basically equivalent to that of the L96 conjugate RZ502031 ( Figure 3 , Table 9).

[0581] Table 9 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0582]

[0583] Example 4: In vivo activity evaluation of three clusters of CR01021 vectors and three clusters of CR01020 vectors conjugated with SOD1 target siRNA

[0584] This example uses a method for evaluating the in vivo target gene inhibition activity in mice to evaluate the inhibitory activity of the target gene SOD1 in mice by using a siRNA conjugate RZ899022 conjugated with three clusters of CR01021 vectors, a siRNA conjugate RZ899007 conjugated with three clusters of CR01020 vectors, and a conjugate RZ599001 conjugated with an L96 vector at the 3' end of the same SOD1 target siRNA. The difference between the three clusters of CR01021 and the three clusters of CR01020 vectors is that the cyclic core parts are isomers of each other.

[0585] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, 5 mice in each group. Each group of mice was given PBS solution and the siRNA conjugate mentioned in this example by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and 5 mice were killed in each group on the 8th day (D8) after administration. Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0586] The primer sequences of this example are shown in Table 7 in Example 2.

[0587] The results of Example 4 show that the in vivo activities of the siRNA conjugates RZ899022, in which the siRNA sense strand 3' end is conjugated with three clusters of CR01021, and RZ899007, in which the siRNA conjugates RZ899007 are conjugated with three clusters of CR01020, are superior to those of the L96 conjugates RZ599001 ( Figure 4 , Table 10).

[0588] Table 10 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0589]

[0590] Example 5: In vivo activity evaluation of three clusters of CR01024 vectors and three clusters of CR01025 vectors conjugated with SOD1 target siRNA

[0591] This example uses a method for evaluating the target gene inhibition activity in mice to evaluate the inhibitory activity of the target gene SOD1 in mice by using a siRNA conjugate RZ899023 conjugated with three clusters of CR01024 vectors, a siRNA conjugate RZ899024 conjugated with three clusters of CR01025 vectors, and a conjugate RZ599001 conjugated with L96 at the 3' end of the same SOD1 target siRNA. The three clusters of CR01024 and the three clusters of CR01020 have the same circular core structure, but use linkers of different lengths, and CR01025 and CR01021 have the same circular core structure, but use linkers of different lengths.

[0592] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, 5 mice in each group. Each group of mice was given PBS solution and the siRNA conjugate mentioned in this embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and the mice were killed on the 8th day (D8) after administration. Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0593] The primer sequences of this example are shown in Table 7 in Example 2.

[0594] The results of Example 5 show that the in vivo activity of the conjugates RZ899023 and RZ899024 of the 3' end of the siRNA sense strand conjugated with three clusters of CR01024 and three clusters of CR01025 is better than that of the L96 conjugate RZ599001 ( Figure 5 , Table 11).

[0595] The results of Example 4 and Example 5 show that different linker lengths have little effect on the activity of the vector.

[0596] Table 11 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0597]

[0598] Example 6: In vivo activity evaluation of three clusters of CR01022 vectors conjugated with CC3 target siRNA

[0599] In this example, the target gene inhibition activity evaluation method in vivo in mice was used to evaluate the inhibitory activity of the siRNA conjugate RZ802010, which was conjugated with three clusters of CR01022 at the 3' end of the sense strand of the same CC3 target siRNA, and the L96 conjugate RZ502031 on the target gene CC3 in mice.

[0600] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 15 mice in each group, a total of 3 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in the present embodiment by subcutaneous administration in the abdomen, wherein the dosage of each mouse in the PBS control group was 5 ml / kg, and the dosage of each mouse in the siRNA conjugate experimental group was 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 15th day (D15), and 5 mice were killed in each group on the 29th day (D29). Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0601] The primer sequences of this example are shown in Table 5 in Example 1.

[0602] The results of Example 6 show that the conjugate RZ802010, in which the 3' end of the siRNA sense strand was conjugated with three clusters of CR01022, has comparable highest inhibitory activity and better sustained efficacy than the L96 conjugate RZ502031 ( Figure 6 , Table 12).

[0603] Table 12 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0604]

[0605] Example 7: In vivo activity evaluation of two clusters of CR01022 vectors and three clusters of CR01022 vectors conjugated with SOD1 target siRNA

[0606] In this example, the target gene inhibitory activity evaluation method in vivo in mice was used to evaluate the inhibitory activity of the siRNA sequence RZ899009 conjugated with three clusters of CR01022 at the 3' end of the positive strand of the same SOD1 target siRNA, the siRNA sequence RZ899011 conjugated with two clusters of CR01022, and the L96 conjugate RZ599001 on the target gene SOD1 in mice.

[0607] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 20 mice in each group, a total of 4 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in the present embodiment by subcutaneous administration in the abdomen, wherein the dosage of each mouse in the PBS control group was 5 ml / kg, and the dosage of each mouse in the siRNA conjugate experimental group was 1 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 15th day (D15), 5 mice were killed in each group on the 29th day (D29), and 5 mice were killed in each group on the 43rd day (D43). Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0608] The primer sequences of this example are shown in Table 7 in Example 2.

[0609] The results of Example 7 show that the siRNA sequence RZ899009 conjugated with three clusters of CR01022 at the 3' end of the siRNA sense strand and the siRNA sequence RZ899011 conjugated with two clusters of CR01022 have basically the same highest inhibitory activity and sustained efficacy on the target gene SOD1, and are both superior to the L96 conjugated sequence RZ599001 ( Figure 7 , Table 13).

[0610] Table 13 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0611]

[0612] Example 8: In vivo activity evaluation of one cluster of CR01022 vectors and two clusters of CR01022 vectors conjugated with SOD1 target siRNA

[0613] In this example, the in vivo target gene inhibitory activity evaluation method of mice was used to evaluate the inhibitory activity of the same SOD1 target siRNA in vivo, including the siRNA sequence RZ899011 conjugated with two clusters of CR01022 vectors at the 3' end of the positive strand, the siRNA sequence RZ899040 conjugated with one cluster of CR01022, and the L96 conjugate RZ599001, on the target gene SOD1.

[0614] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, 5 mice in each group. Each group of mice was given PBS solution and the siRNA conjugate mentioned in this embodiment by subcutaneous administration in the abdomen, wherein the dosage of each mouse in the PBS control group was 5 ml / kg, and the dosage of each mouse in the siRNA conjugate experimental group was 1 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and mice were killed on the 8th day (D8) after administration. Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0615] The primer sequences of this example are shown in Table 7 in Example 2.

[0616] The results of Example 8 show that the siRNA sequence RZ899011 conjugated with two clusters of CR01022 and the siRNA sequence RZ899040 conjugated with one cluster of CR01022 at the 3' end of the siRNA sense strand can produce a highly effective inhibitory effect on the target gene SOD1 at D8, and the inhibitory activity is basically equivalent, and both are slightly better than the L96 conjugate RZ599001 ( Figure 8 , Table 14).

[0617] Table 14 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0618]

[0619]

[0620] Example 9: In vivo activity evaluation of two clusters of CR01026 vectors and two clusters of CR01022 conjugated SOD1 target siRNA

[0621] This example uses a method for evaluating the inhibitory activity of target genes in vivo in mice to evaluate the inhibitory activity of the target gene SOD1 in mice by conjugating two clusters of CR01026 vector siRNA sequence RZ899025, two clusters of CR01022 vector siRNA sequence RZ899011, and L96 conjugate RZ599001 to the 3' end of the positive chain of the same SOD1 target siRNA. The two clusters of CR01026 and the two clusters of CR01022 have the same annular core structure, but use linkers of different lengths.

[0622] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 20 mice in each group, a total of 4 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in this embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and 5 mice were killed in each group on the 8th day (D8) after administration, 5 mice were killed in each group on the 29th day (D29), 5 mice were killed in each group on the 43rd day (D43), and 5 mice were killed in each group on the 57th day (D57). Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0623] The primer sequences of this example are shown in Table 7 in Example 2.

[0624] The results of Example 8 show that the siRNA sense strand 3' end conjugated with the siRNA sequence RZ899025 of the two clusters CR01026 and the siRNA sequence RZ899011 of the two clusters CR01022 had comparable in vivo activity to the L96 conjugated sequence RZ599001 at D8 and D29, and significantly better in vivo activity than the L96 conjugated sequence RZ599001 at D43, indicating that the two clusters CR01026 conjugate RZ899025 and the two clusters CR01022 conjugate RZ899011 had better pharmacodynamics and sustained effects than the L96 conjugate RZ599001, and different linker lengths had little effect on the activity of the CR01026 and CR01022 vectors ( Fig. 9 , Table 15).

[0625] Table 15 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0626]

[0627] Example 10: In vivo activity evaluation of three clusters of CR01023 vectors conjugated with CC3 target siRNA

[0628] This example uses a method for evaluating the in vivo target gene inhibition activity in mice to evaluate the inhibitory activity of the siRNA sequence RZ802011 conjugated to three clusters of CR01023 vectors at the 3' end of the sense strand of siRNA, and the L96 conjugate RZ502031 on the target gene CC3 in mice.

[0629] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 15 mice in each group, a total of 3 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in this embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on D8, 5 mice were killed in each group on D15, and 5 mice were killed in each group on D29. Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-timePCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0630] The primer sequences of this example are shown in Table 5 in Example 1.

[0631] The results of Example 10 show that the three-cluster CR01023 conjugate RZ802011 is compared with the L96 conjugate RZ502031. The overall activity of the two groups of test substances is comparable at D8 and D15, but at D29, the L96 conjugate RZ502031 has a relatively higher target gene inhibition effect. Fig.10 , Table 16).

[0632] Table 16 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0633]

[0634] Example 11: In vivo activity evaluation of three clusters of CR01023 vectors conjugated with SOD1 target siRNA

[0635] In this example, the target gene inhibition activity evaluation method in vivo in mice was used to evaluate the inhibitory activity of the siRNA sequence RZ899010, which was conjugated with three clusters of CR01023 at the 3' end of the siRNA sense strand, and the L96 conjugate RZ599001 on the target gene SOD1 in mice.

[0636] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 15 mice in each group, a total of 3 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in the present embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg in the administration volume, and each mouse in the siRNA conjugate experimental group was given a dose of 1 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 15th day (D15), and 5 mice were killed in each group on the 29th day (D29). Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0637] The primer sequences of this example are shown in Table 7 in Example 2.

[0638] The results of Example 11 showed that the three-cluster CR01023 conjugate RZ899010 was compared with the L96 conjugate RZ599001. The overall activity of the two groups of test substances was comparable at D8 and D15, but at D29, the L96 conjugate RZ599001 had a relatively higher target gene inhibition effect ( Fig.11 , Table 17).

[0639] Table 17 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0640]

[0641] Example 12: In vivo activity evaluation of two clusters of CR01027 vectors and two clusters of CR01022 vectors conjugated with SOD1 target siRNA

[0642] This example uses the method for evaluating the in vivo target gene inhibition activity in mice to evaluate the inhibitory activity of the siRNA sense strand 3' end conjugated with the siRNA sequence RZ899048 of the two clusters of CR01027 vectors, the siRNA sequence RZ899011 of the two clusters of CR01022 vectors, and the conjugate RZ599001 conjugated with L96 on the target gene SOD1 in mice. The difference is that CR01027 adds a methoxy group at the 1 position of the CR01022 mother core structure.

[0643] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, 5 mice in each group. Each group of mice was given the siRNA conjugate mentioned in this embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg, and the administration volume was 5 mL / kg. The day of administration was recorded as the first day (D1), and 5 mice were killed in each group on the 8th day (D8) after administration. Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0644] The primer sequences of this example are shown in Table 7 in Example 2.

[0645] The results of Example 12 show that the conjugate RZ899048 of cluster 2 CR01027 has a higher target gene inhibition effect at D8 than the conjugate RZ599001 of L96, and the effect is comparable to the conjugate (RZ899011) of cluster 2 CR01022 ( Fig.12 , Table 18).

[0646] Table 18 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0647]

[0648] Example 13: In vivo activity evaluation of two clusters of CR01027 vectors conjugated to angiopoietin-like 3 (ANGPTL3) target siRNA

[0649] This example uses a method for evaluating the in vivo target gene inhibition activity in mice to evaluate the inhibitory activity of the siRNA sequence RZ897013 conjugated to the two-cluster CR01027 vector at the 3' end of the positive strand of the siRNA, and the conjugate RZ597002 conjugated to L96 on the target gene ANGPTL3 in mice.

[0650] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 5 mice in each group, a total of 4 groups. Each group of mice was given the siRNA conjugate mentioned in this example by subcutaneous administration in the abdomen, and each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg, and the administration volume was 5 mL / kg. The day of administration was recorded as the first day (D1), and 5 mice were killed in each group on the 8th day (D8) after administration. Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0651] The primer sequences of this example are shown in Table 19.

[0652] Table 19 Primer sequence table

[0653]

[0654] The results of Example 13 show that the second cluster CR01027 conjugate RZ897013 has a comparable inhibitory effect compared to the L96 conjugate RZ597002 ( Fig.13 , Table 20).

[0655] Table 20 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0656]

[0657] Example 14: In vivo activity evaluation of two clusters of CR01017 vectors and two clusters of CR01022 vectors conjugated with SOD1 target siRNA

[0658] This example uses a method for evaluating the inhibitory activity of target genes in vivo in mice to evaluate the inhibitory activity of the 3' end of the positive strand of the SOD1 target siRNA conjugated with two clusters of CR01017 vectors, siRNA sequence RZ899038, two clusters of CR01022 vectors, and L96 conjugate RZ599001 on the target gene SOD1 in mice. The main difference between the two clusters of CR01017 vectors and the two clusters of CR01022 vectors is that the linker part of the CR01017 vector is an amide bond structure, and the linker part of the CR01022 vector is a triazole structure.

[0659] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 15 mice in each group, a total of 4 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in the present embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg in the administration volume, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 29th day (D29), and 5 mice were killed in each group on the 54th day (D54). Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0660] The primer sequences of this example are shown in Table 7 in Example 2.

[0661] The results of Example 14 show that the in vivo activity of the siRNA sense strand 3' end conjugated with the siRNA sequence RZ899038 of the two clusters CR01017 vector and the siRNA sequence RZ899011 of the two clusters CR01022 vector is better than that of the L96 conjugated sequence RZ599001, and the use of the linker triazole structure (CR01022) or amide structure (CR01017) has little effect on the activity of the vector ( Fig.14 , Table 21).

[0662] Table 21 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0663]

[0664] Example 15 In vivo activity evaluation of different amounts and locations of CR01017 conjugated to SOD1 target siRNA

[0665] In this example, the target gene inhibitory activity evaluation method in vivo in mice was used to evaluate the inhibitory activity of siRNA sequence RZ897041 with a cluster of CR01017 vectors conjugated to the 3' end of the siRNA sense chain, siRNA sequence RZ897042 with a cluster of CR01017 vectors conjugated to the 5' and 3' ends of the siRNA sense chain, siRNA sequence RZ897038 with two clusters of CR01017 vectors conjugated to the 3' end of the siRNA sense chain, and L96 conjugate RZ599001 on the target gene SOD1 in mice.

[0666] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 15 mice in each group, a total of 5 groups. Each group of mice was given PBS solution or siRNA conjugates mentioned in this embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg in the administration volume, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 29th day (D29), and 5 mice were killed in each group on the 54th day (D54).

[0667] The primer sequences of this example are shown in Table 7 in Example 2.

[0668] The results of Example 15 show that the siRNA conjugate RZ899038, in which the 3' end of the siRNA sense strand is conjugated to a two-cluster CR01017 vector, the siRNA conjugate RZ899041, in which the 3' end of the siRNA sense strand is conjugated to a one-cluster CR01017 vector, and the siRNA conjugate RZ899042, in which the 5' end and the 3' end of the siRNA sense strand are conjugated to a one-cluster CR01017 vector, respectively, have an inhibitory effect comparable to that of the L96 conjugate RZ599001 at D8 and D29, and have a higher inhibitory effect on the target gene than the L96 conjugate RZ599001 at D59. This indicates that the CR01017 conjugate has a longer duration of pharmacodynamic action ( Fig.15 , Table 22).

[0669] Table 22 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0670]

[0671]

[0672] Example 16: The present disclosure selects two clusters of CR01022 conjugated with SOD1 target siRNA sequence RZ899011 and two clusters of CR01017 vector conjugated with SOD1 target siRNA sequence RZ899038 for in vivo toxicity evaluation in mice

[0673] In this example, subcutaneous injection was used to evaluate the nature and extent of the toxicity of the siRNA sequence RZ899011 conjugated with two clusters of CR01022 and the siRNA sequence RZ899038 conjugated with two clusters of CR01017 vectors in ICR mice.

[0674] ICR mice aged 6-8 weeks were randomly divided into groups according to body weight, with 10 mice (half male and half female) in each group, for a total of 3 groups. Each group of mice was subcutaneously administered with PBS solution (without siRNA conjugate) or the siRNA conjugate mentioned in this example, wherein each mouse in the PBS control group was administered with a dose of 10 ml / kg mouse body weight, and each mouse in the siRNA conjugate administration group was administered with a dose of 300 mg / kg mouse body weight (in terms of siRNA), and the administration volume was 10 ml / kg.

[0675] The day of administration was recorded as the first day (D1), and clinical observation was performed at least once a day after the first administration during the experiment; blood was collected from all animals on the 15th day of the experiment (recorded as D15) (mice were fasted for at least 12 hours before sampling and testing, but water was not allowed) for hematological and blood biochemical tests. The collected blood was anticoagulated with EDTA-K2, and a routine blood test was performed using an automatic modular blood and body fluid analyzer (Sysmex XN-10B1); the collected blood was anticoagulated with sodium citrate, centrifuged at room temperature for 10 minutes (centrifugal force of about 2000g), and the plasma was separated and tested for coagulation indexes using a fully automatic coagulation analyzer (Mindray C3510); blood samples (without anticoagulation) were collected and placed at room temperature for about 30 minutes. After the blood coagulated, it was centrifuged at 2000g for 10 minutes at 4°C, and a fully automatic biochemical analyzer (Sysmex BX-4000) was used for blood biochemical testing. All animals were dissected on the 15th day of the experiment (denoted as D15). The mice to be dissected had to fast but not deprive of water for at least 12 h before dissection, and were anesthetized with Zotal 50 (Vicki Co., Ltd., France, 8G4VA). After blood collection, the animals were euthanized by bleeding from the abdominal aorta, and their gross anatomical observations were performed. The livers of all animals were subjected to histopathological examination (using hematoxylin-eosin staining), and if necessary, histopathological examinations were performed on organs with obvious abnormal changes in size, shape, color, texture, etc.

[0676] The primer sequences of this example are shown in Table 7 in Example 2.

[0677] The results of Example 16 show that after the siRNA conjugates described in this example, no abnormalities were found in the clinical observations of the PBS group, the RZ899011 group, and the RZ899038 group during the experiment; at the end point of the experiment D15, no obvious abnormalities were found in the gross anatomy; no abnormalities were found in the hematology and blood biochemistry tests of the animals in each group ( Fig.16a -j, Table 23); no abnormalities were found in the histopathological staining of the liver tissues of the animals in each group ( Figure 16k ); indicating that the siRNA conjugates and their carrier molecules disclosed in the present invention have good safety and low animal level toxicity.

[0678] Table 23 Results of hematological and blood biochemical tests in mice after administration of the siRNA conjugates described in this example

[0679]

[0680]

[0681] The above is only an exemplary embodiment of the present disclosure. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present disclosure. These improvements and modifications should also be regarded as the scope of protection of the present disclosure.

Claims

1. A compound having a structure represented by formula (Ia) or a stereoisomer thereof, a pharmaceutically acceptable salt or a prodrug thereof: In formula (Ia), R1 is selected from H, a hydroxyl protecting group or The * represents a connection site for connecting a drug active molecule; The R2 is selected from H, a reactive phosphorus group or in, R 2b Selected from a solid phase carrier containing an amino functional group, R 2a A covalent linking group selected from the group consisting of a covalent linking group connected to the amino functional group; The j is selected from 0, 1, 2 or 3; Each M is independently selected from hydroxyl or thiol; Each p is independently selected from 0, 1, 2, 3 or 4; Each q is independently selected from 0, 1, 2, 3 or 4; Each Cy is independently selected from wherein A is selected from a 5-6 membered oxygen-containing heterocyclic ring; R3 is selected from H or C1-C6 alkoxy; n is selected from 1 or 2; each X is independently selected from O, S, or NH; each R4 is independently selected from H, C1-C6 alkyl or C1-C6 alkoxy; each L1 is independently selected from a substituted or unsubstituted triazole group, or an amide group; m is selected from 1 or 2; each L2 is independently selected from a substituted or unsubstituted C1-C30 alkylene group or Each r is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, each Z is independently selected from O, S or NH, each R L2 Each is independently selected from substituted or unsubstituted C1-C10 alkylene; each Y is independently selected from O, S or NH; each R5 is independently selected from H, substituted or unsubstituted C1-C4 alkylacyl or substituted or unsubstituted C6-C 12 Aryl acyl.

2. The compound according to claim 1, characterized in that A is selected from a 5- to 6-membered saturated oxygen-containing heterocyclic ring; Optionally, A is selected from a 5-6 membered saturated heterocyclic ring containing one oxygen atom; Optionally, said m is selected from 1; Optionally, X is selected from O; Optionally, each R4 is H; Optionally, each L1 is independently selected from Optionally, each L1 is selected from Optionally, each L1 is selected from Optionally, the R3 is selected from H or C1-C3 alkoxy; Optionally, said R3 is selected from H or methoxy; Optionally, each L2 is independently selected from Each r is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, each Z is independently selected from O, S or NH, each R L2 Each is independently selected from substituted or unsubstituted C1-C10 alkylene; Optionally, each L L2 Each is independently selected from substituted or unsubstituted C1-C5 alkylene; Optionally, each L L2 Each is independently selected from substituted or unsubstituted C1-C3 alkylene; Optionally, each L L2 Each is independently selected from substituted or unsubstituted C2 alkylene; Optionally, each r is independently selected from 2 or 3; Optionally, each L2 is independently selected from The r is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; Optionally, each L2 is independently selected from The r is selected from 2 or 3; Optionally, Y is selected from O; Optionally, each R5 is independently selected from H, Optionally, each R5 is selected from Optionally, each R5 is selected from H; Optionally, p and q are each independently selected from 0 or 1; Optionally, p=1 and q=1, or p=1 and q=0, or p=0 and q=1, or p=0 and q=0; Optionally, p=1 and q=0; Optionally, the hydroxy protecting group is selected from trityl, 4-methoxytrityl, 4,4'-dimethoxytrityl or 4,4',4"-trimethoxytriphenyl; Optionally, the hydroxy protecting group is selected from 4,4'-dimethoxytrityl; Optionally, the reactive phosphorus group is selected from Optionally, the reactive phosphorus group is selected from Optionally, the pharmaceutically active molecule is selected from a small molecule drug, an antibody or an oligonucleotide; Optionally, the oligonucleotide is selected from a single-stranded oligonucleotide and a double-stranded oligonucleotide; Optionally, the pharmaceutically active molecule is selected from double-stranded oligonucleotides; Optionally, the double-stranded oligonucleotide is selected from siRNA; Optionally, the solid support is selected from a resin containing an amino functional group or a controlled pore glass bead containing an amino functional group; Optionally, R 2b Selected from represents resin or controlled pore glass beads; Optionally, R 2a Selected from Optionally, Selected from Optionally, the j is selected from 0, 1 or 2 Optionally, said j is selected from 0; Optionally, said j is selected from 1; Optionally, j is selected from 2.

3. The compound according to claim 1, characterized in that Each Cy is independently selected from any of the following structures:

4. The compound according to claim 1, characterized in that The compound is selected from any of the following structures:

5. The compound according to claim 1, characterized in that The compound is selected from any of the following compounds:

6. A conjugate having a structure represented by formula (Ib) or a stereoisomer thereof, a pharmaceutically acceptable salt or a prodrug thereof: In formula (Ib), Nu represents an oligonucleotide; The k is selected from 1 or 2; The structural formula of Q is in, The j' is selected from 1, 2, 3 or 4; the *, M, p, q, Cy are as defined in any one of claims 1 to 5.

7. The conjugate according to claim 6, characterized in that The j' is selected from 1, 2 or 3; Optionally, said j' is selected from 1; Optionally, said j' is selected from 2; Optionally, said j' is selected from 3; Optionally, said k is selected from 1; Optionally, said k is selected from 2; Optionally, the oligonucleotide is selected from a single-stranded oligonucleotide or a double-stranded oligonucleotide; Optionally, said Nu represents a double-stranded oligonucleotide; Optionally, the double-stranded oligonucleotide is selected from siRNA; Optionally, the k is selected from 1; and one Q is conjugated to the 3' end of the siRNA sense strand, Optionally, the k is selected from 2, and the two Qs are conjugated to the 3' end and 5' end of the siRNA sense strand, respectively.

8. The conjugate according to claim 6, characterized in that The conjugate has any of the following structures:

9. The conjugate according to claim 6, characterized in that The conjugate is selected from any one of the following compounds:

10. A composition, characterized in that The composition comprises the conjugate according to any one of claims 6 to 9; Optionally, the composition further comprises one or more pharmaceutically acceptable carriers or excipients.

11. Use of any of the following in the preparation of a medicament for preventing and / or treating a disease: (I), a compound according to any one of claims 1 to 5; and / or (II), the conjugate according to any one of claims 6 to 9; and / or (III) The composition of claim 10; Optionally, the disease is selected from a liver-related disease.

12. Use of any of the following in the preparation of a drug for reducing target gene expression or activity: (I), a compound according to any one of claims 1 to 5; and / or (II), the conjugate according to any one of claims 6 to 9; and / or (III) The composition according to claim 10.

13. A drug, characterized in that Includes any of the following items and pharmaceutically acceptable excipients or adjuvants: (I), a compound according to any one of claims 1 to 5; and / or (II), the conjugate according to any one of claims 6 to 9; and / or (III) The composition according to claim 10.

14. A pharmaceutical combination, characterized in that The method comprises the drug according to claim 13 and any other active ingredients.

15. A method for treating and / or preventing a disease in a subject, characterized in that It comprises administering to a subject a pharmaceutically acceptable amount of any of the following: (I), the conjugate according to any one of claims 6 to 9; and / or (II) the composition according to claim 10; and / or (III), the medicament according to claim 13; and / or (IV) The pharmaceutical combination according to claim 14.

16. A method for reducing the expression or activity of a target gene, characterized in that: It includes contacting the cell with any of the following: (I), the conjugate according to any one of claims 6 to 9; and / or (II), the composition according to claim 10; and / or (III), the medicament according to claim 13; and / or (IV) The pharmaceutical combination according to claim 14.

Citation Information

Patent Citations

  • Branched chain-type derivative having glucoskeleton

    JP1994009675A

  • N-ACETYLGALACTOSAMINE(GAlNAc)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES

    WO2022076922A1

  • Nucleic acid ligand and conjugate thereof, and preparation method therefor and use thereof

    WO2023274395A1